Download 2016 Annual Report - Cancer Research Institute

2016
ANNUAL REPORT
From Our Leadership
OUR MISSION:
SAVE MORE LIVES
We fuel the discovery and development of powerful
immunotherapies for all types of cancer.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to
harnessing the immune system’s power to conquer all cancers. We fund the most innovative research of
young scientists, invest in clinical studies of promising new treatments, and provide patients and caregivers
with information on the latest advances in cancer immunotherapy. With more than 60 years of experience
funding research on the immune system and cancer, CRI is leading the way and ushering in a new era when
patients, with all types of cancer, can be treated and potentially cured with immunotherapy.
1
From Our Leadership
2
Postdoctoral Fellows
4
Translational Research
6
Clinical Accelerator
8
Drug Development
10 Scientific Dialogue
12 Awareness & Education
14 Awards & Honors
16 Fiscal Year 2016
Grants & Awards
30 Fundraising
32 Donors
46 Financial Highlights
48 Governance & Guidance
IN 2016, CRI SUPPORTED LABORATORY,
TRANSLATIONAL, AND CLINICAL RESEARCH IN
13 COUNTRIES, INCLUDING 20 U.S. STATES.
J
ust five years ago, when talking about outcomes of
patients treated for late-stage cancers, “cure” wasn’t a
word our scientists were likely to use. Today, the outlook
is significantly better, with cancer immunotherapy now offering
patients a real chance—not only at surviving longer, but also
at living better without the debilitating side effects often seen
with conventional cancer treatments. At last, we can say that
cures for cancer are within reach.
This didn’t happen overnight. It has taken a long view of
progress and decades of research to build a foundation for the
new therapies available to patients today. Lifesaving drugs
like the FDA-approved immunotherapies Yervoy®, Opdivo®,
Keytruda®, Imlygic®, and others are built upon fundamental
knowledge of the immune system, its components, and how
they function. This knowledge was hard won by a global
community of immunologists and tumor immunologists, many
of whom have relied on funding from the Cancer Research
Institute to carry out their important work.
In fiscal year 2016 (July 1, 2015, to June 30, 2016), we
continued to push the limits of human knowledge and open the
way for new and more effective immunotherapies by awarding
over $23.6 million to support highly promising laboratory,
translational, and clinical research around the world.
We also recognize the need to help patients and their
caregivers navigate what can be an overwhelming introduction
to this new treatment approach. In 2016, we invested in
educational programming to provide them trusted information
and connect them to immunotherapy clinical trials. And
as part of our Cancer Immunotherapy Month awareness
campaign in June, we introduced more than 3.8 million people
worldwide to the exciting progress being made today thanks to
immunotherapy breakthroughs.
We are proud that we are able to make these important
contributions to the global cancer research and patient
communities while also maintaining our high ratings with
charity watchdogs, including four out of four stars from Charity
Navigator and membership within the Better Business Bureau’s
Wise Giving Alliance, among others.
None of this lifesaving work would be possible without the
generous support of our donors like you, on whom we rely. We
extend our heartfelt thanks on behalf of the thousands of
CRI-funded scientists and the millions of cancer patients
worldwide who may benefit from your support.
PAUL C. SHIVERICK
Co-Chairman of the Board
ANDREW K. TSAI
Co-Chairman of the Board
JAMES P. ALLISON, PH.D.
Director, Scientific Advisory Council
JILL O’DONNELL-TORMEY, PH.D.
CEO and Director of Scientific Affairs
58 Ways to Give
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
1
POSTDOCTORAL
FELLOWS
29
NEW GRANTS
$5.1
MILLION
AWARDED
IMPACT
Powering Innovation
The CRI Irvington Postdoctoral Fellowship Program provides
training and financial support to young scientists working in the
laboratories of leading cancer immunologists around the world.
Fellowships provide up to $175,500 over three years.
O
ur postdoctoral fellows are the best and the brightest, bringing
new energy to tackle the most pressing areas of research today.
Their investigations deepen our knowledge of the immune
system and lay the foundation for new immunotherapies for all types of
cancer. In the past year:
Leticia Corrales, Ph.D., of the University of Chicago, in Chicago,
IL, engineered a small molecule of PD-1 and demonstrated its
effectiveness in treating both small and large colorectal cancer
tumors.
Rony Dahan, Ph.D., of The Rockefeller University, in New York, NY,
demonstrated how the tail region of checkpoint inhibitor antibodies
can affect immunotherapy responses, providing key insights to
support the development of next-generation checkpoint inhibitors.
P.C. Dave P. Dingal, Ph.D., of Stanford University School of
Medicine, in Stanford, CA, created a system that allows researchers
to manipulate the activity of genes to better characterize and
understand the immune system’s dynamics.
Bengt Martin Gustavsson, Ph.D., of the University of California, San
Diego, in San Diego, CA, developed new ways to design and analyze
the binding affinity of a key immune molecule, called a chemokine, to
enable more effective drug design.
Jiazhi Hu, Ph.D., of the Boston Children’s Hospital, in Boston, MA,
discovered how enzymes called RAGs can cause improper DNA
rearrangements that have been implicated in B cell lymphoma,
a deadly type of blood cancer.
Helene M. Salmon, Ph.D., of the Icahn School of Medicine at Mount
Sinai, in New York, NY, revealed how dendritic cells coordinate
anti-melanoma responses, and developed an approach to enhance
their anti-cancer activity in combination with checkpoint inhibitors.
CRI is at the forefront of
supporting innovative and
highly promising research. As
a postdoctoral fellow, I relied
on CRI’s funding of my basic
research, considered at the
time by some as lacking cancer
relevance. Yet, it turned out
that it’s now one of the main
focuses in cancer therapy
development.
RONY DAHAN,
BENGT MARTIN
GUSTAVSSON,
P.C. DAVE P. DINGAL,
AND MARGARET K.
CALLAHAN
Estela P. Jacinto, Ph.D.
Associate Professor,
Rutgers University
CRI Irvington Postdoctoral Fellow,
1999-2002
FDA Approval
M
argaret K. Callahan, M.D., Ph.D., recently the Lloyd J. Old
Memorial Fellow at Memorial Sloan Kettering Cancer Center
in New York, NY, demonstrated in a phase III clinical trial
for metastatic melanoma that combining the immunotherapies
ipilimumab (Yervoy®) and nivolumab (Opdivo®) resulted in
significantly longer progression-free survival than ipilimumab
alone. In fiscal year 2016, the combination received FDA approval
as a first-line treatment for melanoma.
For a complete list of all 102
postdoctoral fellows active in FY2016,
go to page 18
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
3
TRANSLATIONAL
RESEARCH
12
NEW GRANTS
$2.4
Bridging Basic and
Clinical Science
The Clinic and Laboratory Integration Program (CLIP)
supports scientists conducting translational research aimed
at improving the effectiveness of immunotherapies. CLIP
grants provide up to $200,000 over two years.
R
ecent clinical outcomes from immunotherapy trials have generated
new scientific questions and high demand for research funding.
CRI established CLIP to facilitate better dialogue between the
laboratory and clinic. By channeling support into this “translational” area,
CRI supports an iterative research loop that can lead to new and more
effective immunotherapies.
It’s difficult to secure funding
for applied research projects
like ours, and this unique
grant allows us to pursue
our efforts to improve the
effectiveness of cancer
immunotherapy.
MILLION
AWARDED
Michael S. Goldberg, Ph.D.
Assistant Professor of Cancer
Immunology & Virology,
Dana-Farber Cancer Institute
CLIP Investigator, 2014-2016
IMPACT
Power of Biomarkers
H
aidong Dong, M.D., Ph.D., a 2015-2017 CLIP investigator and
associate professor of immunology at the Mayo Clinic in
Rochester, MN, discovered that the Bim biomarker on T
cells can predict how well patients might potentially respond to
Seeking Out
Immunosuppression
in Ovarian Cancer
Novel Target
for Cancer
Immunotherapy
Beyond PD-1: In
Search of a New
Checkpoint Inhibitor
Juan R. Cubillos-Ruiz, Ph.D.
Assistant Professor of Microbiology
and Immunology, Weill Cornell
Medicine, New York, NY
Amanda Lund, Ph.D.
Assistant Professor of Cell &
Developmental Biology; Molecular
Microbiology & Immunology;
and Dermatology, Knight Cancer
Institute, Oregon Health & Science
University, Portland, OR
Mark J. Smyth, Ph.D., FAHMS
Senior Scientist and Immunology
Coordinator, QIMR Berghofer
Medical Research Institute,
Brisbane, Australia
While immune cells can slow
and even halt ovarian cancer
progression, immunosuppressive
factors in the tumor environment
can reduce their potency.
Cubillos-Ruiz is investigating a
newly recognized fatty acid, or
lipid, that enables ovarian tumors
to evade immune attack. He will
study whether blocking the lipid’s
receptor can enhance anti-tumor
immune responses. Promising
results could lead to therapeutic
drug combinations that improve
survival in ovarian cancer patients.
Lund is working to improve our
understanding of how lymphtransporting vessels affect our
immune system’s ability to carry
out anti-tumor immune responses
against melanoma. Abnormal
lymphatic growth is associated with
cancer, and Lund hypothesizes that
tumors may be “hijacking” these
vessels to escape the immune
system. Lund’s work may enhance
immunotherapy approaches that
target these vessels and improve
survival in melanoma patients.
immunotherapy, and provides a way to observe ongoing anticancer immune responses. If validated, this biomarker will help
doctors to monitor an immunotherapy’s effectiveness in patients.
Smyth is exploring a strategy that
targets CD96, a receptor that can
prevent immune cells like natural
killer (NK) cells from eliminating
cancer. He aims to determine
whether blocking CD96 with an
antibody, given alone and in
combination with other treatments,
can improve anti-tumor immunity.
Smyth’s findings may lead to
strategies to reduce tumor
metastases and treat patients
successfully.
For a complete list of all CLIP
investigators active in FY2016,
go to page 22
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT 5
CLINICAL
ACCELERATOR
2
NEW TRIALS
4
EXPANDED TRIALS
A New Clinical
Discovery Model
The Anna-Maria Kellen Clinical Accelerator
is CRI’s venture philanthropy program designed to
help spur the creation of next-generation combination
cancer immunotherapies through partnerships with
academia and industry.
C
RI’s clinical program fosters collaboration across top
academic research groups, biopharma companies, and
nonprofit partners to design, conduct, manage, and fund
scientifically-driven clinical trials with high potential for success.
These trials make available to patients new and promising
treatment combinations that they otherwise could not access.
Prioritized studies are launched with a comprehensive set of
nonprofit resources and a unique IP model that facilitates access to
top drugs from different companies. Clinical Accelerator currently
has more than 15 significant industry and nonprofit partners.
The model is powered by a nonprofit venture capital fund,
which enables it to achieve significant leverage via co-investments
and is structured to become self-sustaining over time via returns
on investment back to the charity as supported drugs demonstrate
their effectiveness. The backbone of the program, the CVC Clinical
Trials Network, is powered by more than 80 clinician scientists
around the world and is managed jointly by CRI and its partner,
Ludwig Cancer Research.
It’s a win-win-win model: cancer patients gain access to
promising new treatment options; scientists gain extraordinary
clinical research and publication opportunities; and company
partners gain valuable investment of nonprofit resources and
expertise into their drugs.
$15.6
David A. Reardon, M.D.
Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
CVC Clinical Trials Network Member, 2012-present
MILLION
AWARDED
IMPACT
CRI’s Clinical Accelerator allows me to provide cutting-edge immunotherapy
combinations to patients with glioblastoma, a type of brain cancer that is
difficult to treat and which may be a promising target for immunotherapy.
Hope for Cancer Patients
T
o date, Clinical Accelerator investments have supported 10
phase I and II cancer immunotherapy clinical trials. These
trials are bringing novel immunotherapy combinations into
the clinic and will ultimately treat over 800 patients spanning
20 types of cancer, including very hard-to-treat cancers like
glioblastoma, a type of brain cancer, triple-negative breast
cancer, and colorectal cancer.
For a complete list of all active
CRI-funded clinical trials, go to
page 25
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
7
DRUG
DEVELOPMENT
23
PUBLICATIONS
TO DATE
12
Harnessing
Industry Expertise
The Cancer Immunotherapy Consortium (CIC) is a think
tank of industry leaders from the cancer immunotherapy
field who seek solutions to challenges in late-stage drug
development, with the goal of accelerating patient benefit.
T
he CIC was founded in 2002 as an international membership
association of pharmaceutical and biotechnology companies
and academic institutions with a common interest in
immunotherapy research and development, with the ultimate goal
of making cancer immunotherapies part of the standard-of-care in
oncology.
With the 2011 FDA approval of ipilimumab (Yervoy®), an immune
checkpoint inhibitor drug, the first milestone toward this goal was
achieved. Given the substantial increase in development activity and
clinical success of other immunotherapy agents that followed, and in
an effort to continue to provide maximum value to the rapidly evolving
field, the direction of the CIC was re-set to become a “think tank” that
would convene and tackle topics of importance to the continued
development of cancer immunotherapies.
The CIC now acts as a neutral platform whereby industry
representatives work together to discuss important issues and
collectively facilitate solutions to challenges in late-stage drug
development, with the goal of accelerating patient benefit. Outcomes
will be available to all stakeholders in the field through publishing
of CIC proceedings. Current topics under review include application
of immune-related Response Criteria (irRC) across clinical studies in
multiple tumor types, and second-generation biomarkers.
Through the CIC, companies
with immunotherapies
in development can work
together toward the same
goal, finding solutions that
will help the entire industry
and, ultimately, cancer
patients.
Daniel S. Chen, M.D., Ph.D.
Vice President, Global Head
of Cancer Immunotherapy
Development,
Genentech/Roche
Co-Chairman, CIC Steering
Committee
INDUSTRY
REPRESENTATIVES
IMPACT
Finding a Common Language
I
n 2016, CIC Steering Committee members identified important
next steps toward the development of shared definitions of
patient outcomes that can be used across different companysponsored drug trials when describing tumor progression within
the context of immunotherapy treatment. The development
of common methods for assessing and reporting patient
outcomes may allow for improved trial design and
generation of data that facilitates FDA review of new
immunotherapies.
To learn more about the Cancer
Immunotherapy Consortium, visit
cancerresearch.org/cic
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
9
SCIENTIFIC
DIALOGUE
1,400+
PARTICIPANTS
375
POSTERS
PRESENTED
Translating Science
Into Survival
The CRI-CIMT-EATI-AACR International Cancer
Immunotherapy Conference is a scientific meeting
devoted to exploring the latest research in cancer
immunology and immunotherapy. It attracts clinicians,
scientists, government regulators, drug developers,
and patient groups.
W
ith the explosion of interest in cancer immunotherapy
and the proliferation of scientific meetings in the field,
the Cancer Research Institute, along with the Association
for Cancer Immunotherapy (CIMT), the European Academy of
Tumor Immunology (EATI), and the American Association for Cancer
Research (AACR), decided to join forces to sponsor the International
Cancer Immunotherapy Conference devoted to exploring the latest
research in cancer immunology and immunotherapy.
The theme of the inaugural September 2015 meeting, held in
New York City, was “Translating Science Into Survival,” and featured
over 60 presentations from leaders in immunology and cancer
immunotherapy. Emerging themes included new genetic targets
for personalized immunotherapies, the relationship between the
microbiome and cancer, and new targets for checkpoint blockade,
chimeric antigen receptor (CAR) treatment, and vaccine therapy.
There was also a snapshot of the regulatory landscape for cell and
gene therapy, biomarkers and their function in patient selection,
imaging and its role in targeting the anti-tumor response, and
immunotherapy trial designs.
The International Cancer Immunotherapy Conference
brings together prominent and promising researchers in
cancer immunology and immunotherapy from around the
world for one of the most important meetings of its kind.
Steven A. Rosenberg, M.D., Ph.D.
Chief, Surgery Branch, Senior Investigator, and Head, Tumor
Immunology Section, National Cancer Institute, NIH
Keynote Speaker, Inaugural International Cancer
Immunotherapy Conference
IMPACT
Convening a Global Audience
T
he September 2015 conference attracted more than 1,400
participants from 38 countries across Asia, Australia, Europe,
North America, and South America. More than 375 scientists
presented their research at the meeting’s poster sessions, and
CRI postdoctoral fellows and other meeting participants took
advantage of the many networking opportunities. Due to high
demand, the organizers hosted a second conference in 2016
in New York City, and a third will take place in Mainz/Frankfurt,
Germany in 2017.
To learn more about
the conference, visit
cancerimmunotherapyconference.org
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
11
AWARENESS
& EDUCATION
Connecting Patients,
Saving Lives
CRI is committed to educating patients, caregivers, and
broader public audiences on important developments in
cancer immunotherapy research and treatment.
C
ancer immunotherapy is a fast-moving field, and keeping up
can be challenging. We provide educational programs and
awareness initiatives designed to reach people who are unaware
of immunotherapy’s promise and connect them to resources and
communities that can help them on their treatment journeys.
Preferred Destination for Trusted Information
More than 1 million website visitors per year rely on free information we
provide on immunotherapy research and treatment for more than 20
different types of cancer.
Immunotherapy Clinical Trial Finder
This fully supported service, the only one of its kind devoted exclusively
to cancer immunotherapy trials, has helped more than 4,500 people
take the first step in exploring their immunotherapy options.
3.8
MILLION PEOPLE
REACHED
500k
VIEWS OF
EDUCATIONAL
PROGRAMMING
IMPACT
Cancer Immunotherapy Month
This series of educational, social, and athletic events in June promotes
awareness of cancer immunotherapy and raises funds to support
lifesaving research. Our most recent June activities featured:
• Immunotherapy Patient Stories: Inspiring videos of patients sharing
their experiences with cancer immunotherapy
• Cancer Immunotherapy and You: Free webinars for patients and
caregivers featuring immunotherapy experts and interactive Q&A
• Immunotherapy and Chemotherapy: What’s the Difference?:
Animated video explaining how these treatments work as well as
their potential benefits and possible side effects
• Ask a Scientist: Short videos inviting immunotherapy experts to
address the most frequently asked questions from patients
• What Cancer Patients Should Know: Latest Immunotherapy News
from ASCO 2016: An expert panel discussing new developments
in cancer immunotherapy research and treatment from the world’s
largest cancer conference
Social Media and Offline Special Events
• #WhiteOutCancer Day: This global social media event invited
people to show their support for cancer immunotherapy research
by wearing white and posting a “selfie” to Facebook, Twitter, and
Instagram or by uploading a personalized message with a photo to
our website at whiteoutcancer.com
• Answer to Cancer Cycling Event: On June 25, 2016, more than
220 cyclists rode 100, 50, or 25 miles through historic West Point
and the surrounding Lower Hudson Valley in New York during this
inaugural fund- and awareness-raising event sponsored by BristolMyers Squibb
• Corporate Events: Participating companies around the world
engaged thousands of their employees in day-long awareness,
education, and fundraising activities designed to highlight progress
in cancer treatment and promote company commitment to social
responsibility and employee health
Thank you to all of our generous partners and supporters
Abbvie; Agenus; Basin Holdings; Bristol-Myers Squibb Company;
Brooklyn Brewery; Celldex Therapeutics, Inc.; Clayton, Dubilier &
Rice, LLC; Debevoise & Plimpton LLP; Finish Line Physical Therapy;
Genentech; Hincapie Sportswear; Holowesko Citadel; Horseneck
Wines & Liquors; Hudson Valley Harvest; Inovio Pharmaceuticals;
LabAnswer and its employees; Merck, known as MSD outside the U.S.
and Canada; Mitsubishi UFJ Securities; Nestle Waters North America;
NewLink Genetics; PPD; Regeneron Pharmaceuticals; Reynolds
Cycling LLC; The Sweat Life; Tailwind Endurance; and USA Cycling
The more people who enter
trials, the more people who
are educated, the more
power we as patients have.
Stephen E.
colorectal cancer survivor
Awareness
O
ur education and public awareness programming reached
more than 3.8 million people last year, introducing them
to cancer immunotherapy breakthroughs and patient
stories of hope, and providing them with information that can
help them or a loved one during a cancer diagnosis. Health
care professionals such as oncology nurses and community
oncologists also found our many resources helpful for their
ongoing professional education.
To learn more, visit
cancerresearch.org/june
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
13
AWARDS
& HONORS
155
SCIENTIFIC AND LAY
INDIVIDUALS AND
ORGANIZATIONS
RECOGNIZED
TO DATE
Recognizing
Excellence
Each year, the Cancer Research Institute honors
individuals and organizations that have made important
contributions to the field of cancer immunotherapy.
I’ve always thought immunotherapy had an enormous
potential to create an ongoing engine of opposition to cancers.
Bill Clinton
42nd President of the United States
Keynote Speaker, CRI 39th Annual Awards Dinner
The William B. Coley Award for Distinguished Research
in Basic Immunology
Alexander Y. Rudensky, Ph.D., Memorial Sloan Kettering Cancer Center,
Howard Hughes Medical Institute, New York, NY, for his contributions to
our understanding of regulatory T cells, which play an important role in
restraining immune responses and inflammation
The William B. Coley Award for Distinguished Research
in Tumor Immunology
Glenn Dranoff, M.D., Novartis Institutes for BioMedical Research,
Cambridge, MA, for his many contributions to the development of
cancer immunotherapies, including the design and testing of the
therapeutic cancer vaccine GVAX
The Frederick W. Alt Award for New Discoveries in Immunology
Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai,
New York, NY, for her pioneering work on dendritic cells, which are key
antigen-presenting cells that play an important role in starting
the immune response
AACR-CRI Lloyd J. Old Award in Cancer Immunotherapy
Ronald Levy, M.D., Stanford University School of Medicine, Stanford,
CA, for his work on developing rituximab (Rituxan®), the first monoclonal
antibody to be approved by the FDA, in 1997
The Oliver R. Grace Award for Distinguished Service
in Advancing Cancer Research
Kenneth C. Frazier, Chairman and CEO, Merck & Co., for advancing
immuno-oncology research and drug development
Lauren S. Veronis, Trustee, Cancer Research Institute, and Former
President, Irvington Institute for Immunological Research, for her many
years of devotion to advancing immunological research through her
leadership and fundraising efforts
THE METROPOLITAN CLUB IN NEW YORK, NY; KENNETH C. FRAZIER AND
CRI TRUSTEE PAUL C. SHIVERICK; ALEXANDER Y. RUDENSKY AND CRI
SCIENTIFIC ADVISOR PHILIP D. GREENBERG; AND LAUREN S. VERONIS AND
CRI CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS JILL O’DONNELL-TORMEY
To view all CRI award recipients,
visit cancerresearch.org/honorees
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
15
FISCAL YEAR 2016
GRANTS & AWARDS
Funding the
Best Science
In fiscal year 2016 (July 1, 2015,
to June 30, 2016), the Cancer
Research Institute awarded more
than $23.6 million for cancer
immunology research and
cancer immunotherapy clinical
development.
*
Denotes grants newly awarded in fiscal year 2016.
All others are active grants awarded in previous years.
22
STATES
13
COUNTRIES
83
INSTITUTIONS
20+
CANCERS
UNDER STUDY
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
17
STUDENT TRAINING AND
RESEARCH IN TUMOR
IMMUNOLOGY (START) PROGRAM
Two-year awards that attract
bright young minds to rewarding
careers as cancer immunologists
by funding graduate studies
in tumor immunology at top
universities.
Lomonosov Moscow State
University, Moscow, Russia
Sergei A. Nedospasov, Ph.D., D.Sc.
Lloyd J. Old Advanced Training
Program in Immunology and
Oncoimmunology
Heng Ru, Ph.D.
Structural and biochemical studies
of the antigen receptor gene
recombination machinery
Liman Zhang, Ph.D.*
Structural studies of NAIP/NLRC4
inflammasomes in immunity and
cancer
Massachusetts General Hospital,
Boston, MA
Alexandria Huynh
The role of PTEN in regulatory
T cell stability and immune
surveillance
CRI IRVINGTON POSTDOCTORAL
FELLOWSHIP PROGRAM
Three-year awards that further
the career development and
advanced laboratory research of
promising postdoctoral fellows
working under the mentorship of
world-class immunologists and
tumor immunologists.
Perelman School of Medicine at
the University of Pennsylvania,
Philadelphia, PA
Thomas Chia Ting Fung
Role of innate lymphoid cellcontrolled intestinal barrier
function in hepatocellular
carcinoma
Boston Children’s Hospital,
Boston, MA
Zhaoqing Ba, Ph.D.*
Mechanisms that mediate intralocus and inter-locus regulation
of V(D)J recombination at
immunoglobulin light chain loci
Samuel and Ruth Engelberg Fellow
Livnat Jerby, Ph.D.*
Integrating CRISPR with singlecell RNA-sequencing to map the
underlying circuits of immune
evasion mechanisms in melanoma
The Hearst Foundations Fellow
Bradley Wayne Blaser, M.D., Ph.D.
Immunologic regulation of
hematopoietic stem cell
engraftment
California Institute of Technology,
Pasadena, CA
Andrew I. Flyak, Ph.D.*
The structural basis of hepatitis
C virus neutralization by broadly
neutralizing human antibodies
University of California, Berkeley,
Berkeley, CA
Thornton William Thompson
The role of oncogene-induced
senescence in promoting antitumor immune responses
F.M. Kirby Fellow
PREDOCTORAL EMPHASIS
PATHWAYS IN TUMOR
IMMUNOLOGY
Four-year awards to universities
to support establishment
and maintenance of tumor
immunology training courses for
graduate students.
Liron David, Ph.D.
Molecular elucidation of the CBM
complex in NFκĸB activation by
antigen receptors
Jiazhi Hu, Ph.D.
Mechanisms that target AID for
antibody gene diversification
and for oncogenic chromosomal
translocations
Robertson Foundation Fellow
Johns Hopkins University School
of Medicine, Baltimore, MD
Director: Charles G. Drake, M.D., Ph.D.
Cheng-Sheng Lee, Ph.D.*
Elucidating the mechanism and
the impact of RAG tracking
University of Colorado,
Denver, CO
Directors: John Kappler, Ph.D.,
and Philippa Marrack, Ph.D.
Immunology / Tumor Immunology
Training Course
Qi Qiao, Ph.D.
Mechanistic elucidation of
activation-induced deaminase in
immunity and cancer
Broad Institute of MIT and
Harvard, Cambridge, MA
Le Cong, Ph.D.*
Dissection of cellular states
and transcriptional networks
regulating innate immunity during
tumorigenesis
Children’s Hospital of
Philadelphia, Philadelphia, PA
Nathan Roy, Ph.D.*
Modulation of T cell trafficking by
Crk adapter proteins
Columbia University Medical
Center, New York, NY
Yenkel Grinberg-Bleyer, Ph.D.
Testing the role of NFĸκB in tumor
immunity through its effect on
regulatory T cells
Dana-Farber Cancer Institute,
Boston, MA
Adam N.R. Cartwright, Ph.D.*
Systematic discovery of
combination immunotherapy
targets
Emory University, Atlanta, GA
William H. Hudson, Ph.D.*
Deciphering the role of long
non-coding RNAs in CD8+ T cell
differentiation
Harvard Medical School,
Boston, MA
Carmen Gerlach, Ph.D.
Differentiation, function, and
dynamic behavior of transitional
memory cells: A novel subset of
CD8+ memory T cells
Alexandra M. Greer, Ph.D.*
The role of ubiquilin-1 in B cell
receptor-driven lymphoma
proliferation
Jason Hudak, Ph.D.
Understanding microbial sensing
in colorectal cancer using
bioorthogonal chemistry
Chaoran Li, Ph.D.*
Differentiation and accumulation
of adipose-tissue regulatory
T cells: Important players in
the immunological control
of metabolism and obesityassociated cancer
Kathleen A. McGuire, Ph.D.
The role of the PD-1/PD-ligand
pathway in anti-tumor immunity
Kristen E. Pauken, Ph.D.
Anti-PD-1 immunotherapy:
Mechanisms and impact on
sustainability of CD8+ T cell
responses
Robertson Foundation Fellow
Harvard T.H. Chan School of
Public Health, Boston, MA
Lior Lobel, Ph.D.*
Identifying novel effectors of the
gut microbiota that modulate
cancer cells killing by CD8+ T cells
using functional metagenomics
Simone Becattini, Ph.D.*
Exploring colonization resistance
against Listeria monocytogenes in
cancer patients
Icahn School of Medicine at
Mount Sinai, New York, NY
Helene M. Salmon, Ph.D.
Contribution of the cutaneous
myeloid network to melanoma
response to therapy
Robertson Foundation Fellow
Pu Gao, Ph.D.
Structural and functional studies of
cytosolic DNA sensing pathway
Robertson Foundation Fellow
Institut Curie, Paris, France
Yvonne K. Mburu, Ph.D.
Mucosal-associated invariant T
cells in anti-tumor therapy
Lloyd J. Old Memorial Fellow
La Jolla Institute for Allergy and
Immunology, La Jolla, CA
Chan-Wang J. Lio, Ph.D.
Role of long non-coding RNAs
in the development of T cell
leukemia
Christophe Pedros, Ph.D.*
Control of regulatory T cell
function by protein kinase C-beta
(PKCη): A novel target for cancer
immunotherapy
Massachusetts Institute of
Technology, Cambridge, MA
Alexandra Boussommier, Ph.D.
Characterizing the role of
macrophages in breast cancer cell
extravasation and recolonization
in organ-specific 3D microfluidic
models
Jesse Green, Ph.D.
Interactions of regulatory T cells
with the tumor endothelium
and effects on the tumor
microenvironment
Samuel and Ruth Engelberg Fellow
Jing-Ping Hsin, Ph.D.
The effects of cellular context on
miR-155 mediated regulation of
gene expression
Young Philanthropists Council
Fellow
Wei Hu, Ph.D.
Tissue repair function of regulatory
T cells during infection and cancer
progression
Fella Tamzalit, Ph.D.
The role of the centrosome in
cytotoxic T cell function
Lloyd J. Old Memorial Fellow
Maria P. Frushicheva, Ph.D.
ZAP-70 and Syk regulation in B cell
chronic lymphocytic leukemia
FELLA TAMZALIT, PH.D.
Li Tang, Ph.D.
T lymphocyte engineering with
interleukin-2-silica nanocapsules
for targeted cancer therapy
Memorial Sloan Kettering Cancer
Center, New York, NY
Michael C. Abt, Ph.D.
Innate immune regulation of C.
difficile-driven inflammation
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
19
NYU Langone Medical Center,
New York, NY
Priya Darshinee A. Issuree, Ph.D.
Roles of Runx3 in inflammatory T
cells and colorectal cancer
Hao Xu, Ph.D.*
Identification of the RORγt ligands,
protein complexes, and targeting
signals involved in Th17 cellmediated homeostasis and
pathogenesis
WEI HU, PH.D.
National Institute of Allergy
and Infectious Diseases,
National Institutes of Health,
Bethesda, MD
Michael G. Constantinides, Ph.D.
Role of the microbiome in lung
cancer
Vanessa K. Ridaura, Ph.D.
Understanding the contributions
of the skin microbiota to efficacy of
melanoma immunotherapy
Ivan Vujkovic-Cvijin, Ph.D.*
Identifying novel microbiomebased immunotherapeutics for
melanoma
National Institute on Aging,
Baltimore, MD
Geoffrey Lovely, Ph.D.*
Watching RAG recombinase
assembly on the IgH locus and offtarget assembly in live pro-B cells
National Institute of Arthritis,
Musculoskeletal, and Skin
Diseases, National Institutes of
Health, Bethesda, MD
Claudia Ouyang, Ph.D.
Non-apoptotic functions of
the TNF-family receptor Fas:
Mechanisms and implications
for autoimmunity and tumor
immunotherapy
Mo Xu, Ph.D.
Intestinal microbiota-induced
Th17 responses in systemic
inflammatory disease
Margaret Dammann Eisner Fellow
Perelman School of Medicine at
the University of Pennsylvania,
Philadelphia, PA
Mohamed Abdel Hakeem, Ph.D.*
Reprogramming of exhausted T
lymphocytes following cure of
chronic viral infection: Implications
for immunotherapy
The Rockefeller University,
New York, NY
Rony Dahan, Ph.D.
Enhancing monoclonal antibodymediated immune responses
within the tumor microenvironment
Harald Hartweger, Ph.D.*
The effect of replicative stresses
on the genesis of chromosome
translocations
Shengdong Ke, Ph.D.
RNA epigenetic HITS-CLIP: A
new approach to understanding
leukemia/lymphoma
Yen-Chih Wang, Ph.D.*
Chemical biology of microbiota
protection against gastrointestinal
cancer
Stanford University School of
Medicine, Stanford, CA
Paola A. Betancur, Ph.D.
In search of the gene regulatory
circuitry responsible for the
transcriptional upregulation of
CD47, the “don’t eat me” signal in
cancer cells
P.C. Dave P. Dingal, Ph.D.
Programmable cancer recognition
using a chimeric system of Notch
and CRISPR
Julia Kennedy-Darling, Ph.D.
Spatially defined immune
cell distribution within tumor
microenvironments before and
after PD-L1 inhibitor treatment
Vincent Christopher Luca, Ph.D.
Deconstructing the structural
mechanisms of cytokine-mediated
JAK activation
Roy Louis Maute, Ph.D.
Characterization of the MHC/
LILRB signaling axis as an
immunotherapeutic target in
cancer
Monica M. Olcina, Ph.D.*
Innate immunity and cancer:
Targeting the complement system
to improve treatment response
Qian Yin, Ph.D.*
Activation of endogenous anergic
self-specific CD8+ T cells by
polymeric nanoparticles for
enhanced cancer immunotherapy
Lloyd J. Old Memorial Fellow
Uniformed Services University
of the Health Sciences,
Bethesda, MD
Maria K. Traver, Ph.D.
Macroautophagic control of
lymphocyte activation and
proliferation
University Health Network,
Toronto, Canada
Christian Bassi, Ph.D.*
Role of HMGB1 in breast cancer
resistance to chemotherapy
Zhenyu Zhong, Ph.D.
Identification of key immune
homeostatic regulators that control
obesity-induced liver inflammation
and disease
Maureen Ann Cox, Ph.D.
Investigation of the role of HMGB1
in asbestos-driven inflammation
and mesothelioma development
Yina Zhu, Ph.D.
Mechanisms that underpin
the sequestration of the tumor
suppressor ebf1 at the nuclear
lamina
University of California, Berkeley,
Berkeley, CA
Michele Ardolino, Ph.D.
MHC-deficient tumors inactivate
infiltrating natural killer cells: A new
target for cancer immunotherapy
Olivia Majer, Ph.D.
Dysregulated Toll-like receptor
responses as an oncogenic driver
April Price, Ph.D.
Expression and function of Toll-like
receptors in intestinal epithelial cells
University of California, San
Diego, La Jolla, CA
Sascha H. Duttke, Ph.D.
Reprogramming macrophage
phenotypes during
immunosurveillance and
neoplastic progression
Bengt Martin Gustavsson, Ph.D.
Structural basis of CXCR7 ligand
binding and signaling
Robertson Foundation Fellow
Hyang-Mi Lee, Ph.D.
Targeting regulatory T cellmediated regulation of IFNγy-driven
anti-tumor immunity
Shabnam Shalapour, Ph.D.
Development of
immunosuppressive plasma
cells that interfere with T celldependent immunogenic cancer
chemotherapy
The University of Chicago,
Chicago, IL
Leticia Corrales, Ph.D.
Study of the regulation of the
STING/IFNβ pathway by the
inflammasome/IL-1 pathway and
its effect in the anti-tumor T cell
response
Stefani Spranger, Ph.D.
The role of tumor-intrinsic
oncogene alterations in immune
evasion of melanoma
University of California, San
Francisco, San Francisco, CA
Hsin Chen, Ph.D.
Mechanisms controlling
lymphocyte retention in and
egress from tissue
University of Minnesota,
Minneapolis, MN
David Lampi Hermanson, Ph.D.
Chimeric antigen receptordirected natural killer cellular
immunotherapy
Adam H. Courtney, Ph.D.
Elucidation of Lck feedback
mechanisms
Robertson Foundation Fellow
Pamela C. Rosato, Ph.D.*
Harnessing tissue resident
memory T cells to combat solid
tumors
Brian R. Graziano, Ph.D.
Using optogenetics to probe
the in vivo biochemistry of cell
movement
Adam J. Litterman, Ph.D.
A global map of mRNA regulatory
elements in CD8+ T cells
Edward W. Roberts, Ph.D.
Lifespan, fate, and function of
immune cells educated in
primary tumors
University of Oxford, Oxford,
United Kingdom
Nathan West, Ph.D.
Analysis of novel susceptibility
genes in chronic intestinal
inflammation and colon cancer
The University of Texas MD
Anderson Cancer Center,
Houston, TX
Ka Ho Stephen Mok, Ph.D.*
Effects of anti-CTLA-4 and
anti-PD-1 on memory T cell
differentiation
Xiaolei Su, Ph.D.
Mechanisms underlying the
dynamic organization of T cell
microclusters
Eugene V. Weissman Fellow
Adam Williamson, Ph.D.
Activation of corpse engulfment
to alleviate tumor-induced
neurotoxicity
The University of Texas
Southwestern Medical Center,
Dallas, TX
Tuo Li, Ph.D.
Roles of mammalian cyclic
dinucleotide signaling in cancer
therapies
Xiaojun Tan, Ph.D.*
Phosphoinositide regulation of
STING trafficking and cancer
immunity
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
21
Haidong Tang, Ph.D.
Tumor-specific LIGHT targeting for
cancer immunotherapy
University of Washington School
of Medicine, Seattle, WA
Jonathan M. Clingan, Ph.D.
Integration of transcriptional and
translational control of the
antiviral response
Elizabeth Gray, Ph.D.
Functional analysis of the
interferon stimulatory DNA
pathway
Marc Joseph Lajoie, Ph.D.*
Protein nanoparticles to elicit
defined T cell response against
cancer cells
University of Wisconsin-Madison,
Madison, WI
Davalyn R. Powell, Ph.D.
The role of neutrophils and
CXCL8-CXCR1/2 signaling in
glioblastoma cell invasion
Vanderbilt University,
Nashville, TN
Katy Beckermann, M.D., Ph.D.*
Metabolic barriers to T cell
function and immunotherapy in
renal cell carcinoma
Merck Fellow
NIR HACOHEN, PH.D.
Washington University School of
Medicine, St. Louis, MO
Jennifer K. Bando, Ph.D.
Immune modulation of dormant
skin tumor development and
persistence
Matthew M. Gubin, Ph.D.
Using genomics to identify targets
of checkpoint blockade cancer
treatment and to identify optimal
target antigens for vaccination
Whitehead Institute for
Biomedical Research,
Cambridge, MA
Yang Eric Guo, Ph.D.
Biogenesis and regulatory functions
of super-enhancer RNAs in cancer
cells of the immune system
Giulia Pasqual, Ph.D.
In vivo tracking of B cell-T cell
interactions in the germinal center
Mohammad Rashidian, Ph.D.
Non-invasive imaging of immune
responses for early detection
of cancer and to monitor
immunotherapy
Kehui Xiang, Ph.D.*
Investigate the importance and
mechanism of poly(A) tail lengthmediated translational control in
different immune cells
Yale University School of
Medicine, New Haven, CT
Najla Arshad, Ph.D.
The effect of tumor-associated
mutant calreticulin on antigen
presentation and tumorigenesis
Will H. Bailis, Ph.D.
Identification and characterization
of immune escape mechanisms
in leukemia
Guoliang Cui, Ph.D.
The influence of nutrient
availability in the tumor
microenvironment on CD8+ T cell
survival and function
Ruth A. Franklin, Ph.D.
The role of macrophages in
tissue homeostasis and tumor
progression
Donald J. Gogel Fellow
Nicola Gagliani, Ph.D.
Targeting Th17 cell plasticity
to control colorectal cancer
development
Dr. Keith Landesman Memorial Fellow
Noah Wolcott Palm, Ph.D.
Role of helminth infections and the
commensal microbiota in intestinal
inflammation
Debrup Sengupta, Ph.D.
Membrane trafficking events
regulating cross presentation
INVESTIGATOR AWARDS
Four-year bridging grants to
assistant professors undertaking
their first independent
investigations in basic and tumor
immunology, designed to provide
flexibility and stability while they
establish their laboratories.
Liang Zhou, M.D., Ph.D.
Northwestern University,
Chicago, IL
Molecular mechanisms of action
of Ahr in T cell differentiation and
function
CLINIC AND LABORATORY
INTEGRATION PROGRAM (CLIP)
Two-year grants that provide
catalytic support for translational
laboratory studies designed to
answer new scientific questions
that arise in the clinic, with
special focus on improving
immunotherapy for cancer
patients.
Austin Health/Ludwig Cancer
Research, Melbourne, Australia
Jonathan S. Cebon, Ph.D., FRACP
Evaluation of ROPN and SPANX
as targets for antigen-specific
immunotherapy
Wade F.B. Thompson Investigator
Brigham and Women’s Hospital/
Harvard Medical School,
Boston, MA
Niroshana Anandasabapathy,
M.D., Ph.D.*
Actioning a newly-defined target
of peripheral tumor-immune
surveillance in dendritic cells
Broad Institute of MIT and
Harvard, Cambridge, MA
Nir Hacohen, Ph.D.
Unbiased single cell analysis of
the lung tumor microenvironment
to understand failure modes of
checkpoint blockade inhibitors
Wade F.B. Thompson Investigator
Cancer Research Center of
Toulouse Purpan, Toulouse,
France
Roland S. Liblau, M.D., Ph.D.
EVER proteins: Immune control
of skin infection by beta-human
papillomaviruses and skin cancer
Columbia University Medical
Center, New York, NY
David M. Owens, Ph.D.
Therapeutic targeting of intrinsic T
cell suppression during anti-tumor
immunity
Dana-Farber Cancer Institute,
Boston, MA
Michael Goldberg, Ph.D.
Use of CRISPR/Cas9 platform to
improve function of cytotoxic T
lymphocytes against melanoma
Fondazione Centro San Raffaele,
Milan, Italy
Matteo Bellone, M.D.
Combining adoptive T cell therapy
to tumor vessel targeting and
checkpoint blockade for cancer
therapy
Icahn School of Medicine at
Mount Sinai, New York, NY
Nina Bhardwaj, M.D., Ph.D.*
Analysis of immune responses
induced by in situ, autologous
therapeutic vaccination against
solid cancers with intratumoral
Poly-ICLC (Hiltonol®)
Joshua Brody, M.D.
Understanding a novel in situ
lymphoma vaccine: Neoantigen
discovery with whole exome
sequencing and neoantigenreactive T cell checkpoint
molecule profiling with CyTOF
La Jolla Institute for Allergy and
Immunology, La Jolla, CA
Stephen P. Schoenberger, Ph.D.
Exome-guided neoantigen
discovery and validation in
head and neck squamous cell
carcinoma
Leiden University Medical Center,
Leiden, The Netherlands
Ferry A. Ossendorp, Ph.D.
Novel vaccine nanoformulations
for clinical mutanome-based
cancer immunotherapy
Massachusetts General Hospital,
Boston, MA
Rakesh K. Jain, Ph.D.
Improving immunotherapy
for metastatic breast cancer
via normalization of the tumor
microenvironment
Andrew D. Luster, M.D., Ph.D.*
Targeting the CXCR3 chemokine
system to improve anti-PD-1
immunotherapy
Mayo Clinic, Rochester, MN
Haidong Dong, M.D., Ph.D.
Monitoring T cell responses
during anti-PD-1 therapy
Medical University of South
Carolina, Charleston, SC
Mark P. Rubinstein, Ph.D.*
Generating human tumor-reactive
T cells with high levels of IL-2Rα for
adoptive T cell therapy
Memorial Sloan Kettering Cancer
Center, New York, NY
Alexander Y. Rudensky, Ph.D.
Immunoregulatory correlates
of a phase I/II study of
mogamulizumab in subjects
with advanced and/or metastatic
solid tumors
Genentech Investigator
Northwestern University,
Chicago, IL
Derek A. Wainwright, Ph.D.*
IDO1 in glioblastoma: Translating
work from mouse to man
Wade F.B. Thompson Investigator
NYU Langone Medical Center,
New York, NY
John Carucci, M.D., Ph.D.
Targeting the immune system to
treat aggressive squamous cell
carcinoma
Oregon Health & Science
University, Portland, OR
Amanda Lund, Ph.D.
FasL-expressing lymphatic vessels
in melanoma
Osaka University, Osaka, Japan
Hiroyoshi Nishikawa, M.D., Ph.D.
Novel cancer immunotherapy
targeting regulatory T cells by antiCCR4 monoclonal antibodies
Ottawa Hospital Research
Institute, Ottawa, Canada
John C. Bell, Ph.D.*
Bioengineering an oncolytic
vaccinia virus to augment the antitumor immune response in human
cancers
QIMR Berghofer Medical
Research Institute, Brisbane,
Australia
Mark J. Smyth, Ph.D., FAHMS
The preclinical validation of CD96
as a checkpoint target for cancer
immunotherapy
Wade F.B. Thompson Investigator
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
23
University of Minnesota,
Minneapolis, MN
Bruce R. Blazar, M.D.
Lymphoid organ repair after cancer
therapy for improving anti-tumor
immune responses
University of Oxford, Oxford,
United Kingdom
Paul Klenerman, M.D., Ph.D.
Licensing human mucosalassociated invariant T cells to kill
hepatocellular carcinomas
BRUCE R. BLAZAR, M.D.
Saint Louis University School of
Medicine, St. Louis, MO
Ryan M. Teague, Ph.D.
Defining the mechanisms of
human T cell rescue by checkpoint
blockade immunotherapy
Stanford University School of
Medicine, Stanford, CA
Dean W. Felsher, M.D., Ph.D.
Oncogene addiction and
immune activation
Holbrook E. Kohrt, M.D., Ph.D.†
T cell biomarker development
for effective immunotherapy for
recurrent non-Hodgkin B cell
lymphoma
The University of Chicago,
Chicago, IL
Thomas F. Gajewski, M.D., Ph.D.
Identification of tumor-intrinsic
signaling pathways that inhibit host
immune responses as potential
therapeutic targets to expand the
applicability of immunotherapy
Oliver R. Grace Investigator
The University of Melbourne,
Melbourne, Australia
Jose A. Villadangos, Ph.D.
Characterization and prevention
of “stunning,” a cytotoxic T
lymphocyte inactivating program
that impairs adoptive cell therapy
against cancer
UCLA Medical Center,
Los Angeles, CA
Roger S. Lo, M.D., Ph.D.
Determinants of responses to
anti-PD-1/PD-L1 therapy and its
combination with BRAF/MEK
co-targeting in melanoma
Wade F.B. Thompson Investigator
Universidad Autónoma de
Madrid, Madrid, Spain
Bruno Sainz Jr., Ph.D.
Role of the innate immune system
in promoting cancer stem cells
University Health Network,
Toronto, Canada
Tak W. Mak, Ph.D., D.Sc., F.R.S.C.*
Evaluating the role of Tosomediated inflammation in
anti-tumor responses
University Hospital of Lausanne,
Lausanne, Switzerland
Daniel E. Speiser, M.D.
Identification and validation of new
targets for cancer immunotherapy
in “exhausted” anti-cancer CD8+ T
cells from mice and humans
University of California, San
Francisco, San Francisco, CA
Markus Muschen, M.D., Ph.D.*
Targeted hyperactivation of B
cell receptor signaling to amplify
therapeutic responses to CART19
treatment
University of Southern California,
Los Angeles, CA
W. Martin Kast, Ph.D.
Anti-CTLA-4 immune modulation
following chemoradiation in
cervical cancer patients
The University of Texas
MD Anderson Cancer Center,
Houston, TX
Michael A. Curran, Ph.D.*
Hypoxia drives tumor immune
suppression and immunotherapy
resistance
University of Virginia Health
System, Charlottesville, VA
Craig L. Slingluff Jr., M.D.
Retention integrins: Induction and
function on cancer-reactive
T lymphocytes
Wade F.B. Thompson Investigator
Vanderbilt University,
Nashville, TN
Jeffrey C. Rathmell, Ph.D.
Metabolic immunosuppression
of T cells in clear cell renal cell
carcinoma and anti-PD-1 therapy
Wade F.B. Thompson Investigator
Walter and Eliza Hall Institute of
Medical Research, Melbourne,
Australia
Nicholas David Huntington, Ph.D.*
Development of a checkpoint
inhibitor that targets the
intracellular protein CIS to enhance
natural killer cell anti-tumor
immunity
Washington University School of
Medicine, St. Louis, MO
Gavin P. Dunn, M.D., Ph.D.*
Monitoring the anti-tumor immune
response in glioblastoma patients
treated with a personalized
neoepitope vaccine
Weill Cornell Medicine,
New York, NY
Juan R. Cubillos-Ruiz, Ph.D.*
Targeting LPA sensors in the tumor
microenvironment to enhance
ovarian cancer immunotherapies
Wade F.B. Thompson Investigator
Yale School of Medicine,
New Haven, CT
Susan M. Kaech, Ph.D.
Enhancing immunotherapy-based
cancer treatments through CD40dependent immunomodulation of
the tumor microenvironment
Wade F.B. Thompson Investigator
COORDINATED CANCER
INITIATIVES
Funding for research in specified
cancer areas deemed able to
provide clinically relevant insights
and discoveries with the potential
to accelerate development of
cancer immunotherapies.
Centre de Lutte Contre Le Cancer
Nantes-Atlantique, Nantes-Saint
Herblain, France
Danila Valmori, Ph.D.
Vaccination strategies for the
treatment of epithelial ovarian
cancer
Icahn School of Medicine at
Mount Sinai, New York, NY
Hearn Jay Cho, M.D., Ph.D.
Vaccine immunotherapy program
in multiple myeloma
Institut Gustave Roussy,
Villejuif, France
Maha Ayyoub, Ph.D.
Role of the gut microbiota in the
ontogeny and homeostasis of
regulatory CD4+ T cells and in
their alteration along immune
responses to ovarian cancer
CLINICAL ACCELERATOR
The Clinical Accelerator brings
together the best capabilities of
the world’s leading academic
researchers, drug companies, and
a unique nonprofit venture fund
to kick-start the development
of powerful new treatments
for cancer patients. To view a
list of all current sites and lead
investigators, go to page 53.
CLINICAL STRATEGY
TEAM GRANTS
Team Leads: Nina Bhardwaj, M.D.,
Ph.D., and Sacha Gnjatic, Ph.D.
Investigators: Eric Schadt, Ph.D.,
Rachel Sabado, Ph.D., Matthew
D. Galsky, M.D., Icahn School of
Medicine at Mount Sinai,
New York, NY
The mutation-derived tumor
landscape of advanced bladder
cancer: A platform to optimize
cancer immunotherapy
Team Lead: John C. Herr, Ph.D.†
University of Virginia Health
System, Charlottesville, VA
Investigators: Victor Engelhard,
Ph.D., Craig Slingluff, M.D., and
Timothy Bullock, Ph.D., and Mark
Kester, Ph.D., University of Virginia
Health System, Charlottesvillel,
VA; Jamal Zweit, Ph.D., Virginia
Commonwealth University,
Richmond, VA
Immunotherapeutic targeting
cell surface neoantigen SAS1B
(Ovastacin, ASTL)
Team Lead: Andrew Sikora, M.D.,
Ph.D., Baylor College of Medicine,
Houston, TX
Investigators: Sacha Gnjatic, Ph.D.,
Icahn School of Medicine at Mount
Sinai, New York, NY; Christine
Chung, M.D., Moffitt Cancer Center,
Tampa, FL; Nham Tran, Ph.D.,
University of Technology, Sydney,
Australia; Cornelis J.M. Melief, M.D.,
Ph.D., Leiden University, Leiden,
The Netherlands
Targeting the tumor immune
microenvironment to enhance
immune-stimulating effects of
chemoradiotherapy
Team Lead: Mark J. Smyth, Ph.D.,
FAHMS, QIMR Berghofer Medical
Research Institute, Brisbane,
Australia
Investigators: Scott J. Antonia,
M.D., Ph.D., Moffitt Cancer Center,
Tampa, FL; Georgina V. Long, Ph.D.,
M.B.B.S., and Richard Scolyer,
M.B.B.S., M.D., Melanoma Institute
of Australia and University of
Sydney, Sydney, Australia; John
Stagg, Ph.D., University of Montréal,
Montréal, Canada
Targeting adenosine in the tumor
microenvironment
Team Leads: Hassane M. Zarour,
M.D., and John M. Kirkwood, M.D.
Investigators: James J. Lee, M.D.,
Mark A. Socinsky, M.D., Adam M.
Brufsky, M.D., Ph.D., University of
Pittsburgh School of Medicine,
Pittsburgh, PA; Alan J. Korman,
Ph.D., Bristol-Myers Squibb,
Redwood City, CA
Targeting multiple inhibitory
receptors in cancer patients
Team Leads: Hideho Okada,
M.D., Ph.D., and Lawrence Fong,
M.D., University of California, San
Francisco, San Francisco, CA
Investigators: Robert P. Edwards,
M.D., Pawel Kalinski, Ph.D.,
University of Pittsburgh School of
†
Deceased
Medicine, Pittsburgh, PA; Kunle
Odunsi, M.D., Ph.D., Roswell Park
Cancer Institute, Buffalo, NY
Enhancing T cell homing to solid
cancers by stimulating proper
chemokines
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
25
Team Lead: Lei Zheng, M.D., Ph.D.,
Investigators: Elizabeth Jaffee, M.D.,
Eric Lutz, Ph.D., Todd Armstron,
Ph.D., Johns Hopkins University
School of Medicine, Baltimore, MD
Tipping the balance in the tumor
microenvironment as a next
generation platform for pancreatic
cancer immunotherapy
CLINICAL TRIALS FUNDED
A first-in-human single ascending
dose study of TRX518 in subjects
with unresectable stage III or stage
IV malignant melanoma or other
solid tumor malignancies
• Henry Koon, M.D., University
Hospitals, Cleveland, OH
• Dale Shepard, M.D., Ph.D.,
Cleveland Clinic, Cleveland, OH
• Jedd D. Wolchok, M.D., Ph.D., and
Margaret Callahan, M.D., Ph.D.,
Memorial Sloan Kettering Cancer
Center, New York, NY
An open label, phase I study of a
neoantigen vaccine (TESLA-001),
with a checkpoint inhibitor, in
patients with metastatic cancer*
• Nina Bhardwaj, M.D., Ph.D., Icahn
School of Medicine at Mount
Sinai, New York, NY
• Gavin Dunn, M.D., Ph.D.,
Washington University
School of Medicine,
St. Louis, MO
A phase I study of NY-ESO-1
vaccine in combination with
ipilimumab in patients with
unresectable or metastatic
melanoma, for whom treatment
with ipilimumab is indicated
• Jonathan S. Cebon, Ph.D., FRACP,
Austin Health/Ludwig Cancer
Research, Melbourne, Australia
• Craig E. Devoe, M.D., North
Shore LIJ, North Shore University
Hospital, Manhasset, NY
• Philip Friedlander, M.D., Icahn
School of Medicine at Mount
Sinai, New York, NY
• Michael A. Postow, M.D.,
Memorial Sloan Kettering Cancer
Center, New York, NY
• Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System, Charlottesville, VA
• Hussein Tawbi, M.D., Ph.D.,
University of Pittsburgh Cancer
Institute, Pittsburgh, PA
Phase I study to assess safety
and tolerability of tremelimumab
and durvalumab, administered
with high dose chemotherapy and
autologous stem cell transplant *
• Hearn Jay Cho, M.D., Ph.D.,
Icahn School of Medicine at
Mount Sinai, New York, NY
• Alexander M. Lesokhin, M.D.,
Memorial Sloan Kettering Cancer
Center, New York, NY
A phase I study to evaluate the
safety and tolerability of antiPD-L1, durvalumab, in combination
with tremelimumab in subjects
with advanced solid tumors
• Kunle Odunsi, M.D., Ph.D., AnnaMaria Kellen Clinical Investigator,
Roswell Park Cancer Institute,
Buffalo, NY
• Patrick Ott, M.D., Ph.D.,
Dana-Farber Cancer Institute,
Boston, MA
• Jedd D. Wolchok, M.D., Ph.D., and
Margaret Callahan, M.D., Ph.D.,
Memorial Sloan Kettering Cancer
Center, New York, NY
A phase I/II dose escalation
study with expansion cohorts to
investigate the safety, biologic and
anti-tumor activity of ONCOS-102
in combination with durvalumab in
subjects with advanced peritoneal
malignancies *
• Dmitriy Zamarin, M.D., Ph.D.,
Memorial Sloan Kettering Cancer
Center, New York, NY
A study of ALK inhibitor, ensartinib,
and anti-PD-L1, durvalumab, in
subjects with ALK-rearranged
non-small cell lung cancer/a
phase I/II study of combination
immunotherapy and mRNA
vaccine in subjects with non-smallcell lung cancer (NSCLC)
• Leena Gandhi, M.D., Ph.D., NYU
Langone Medical Center, New
York, NY
TRIALS SUPPORTED
WITH REAGENTS
A phase I/II study of in situ
vaccination with tremelimumab
and IV durvalumab plus PolyICLC in subjects with advanced,
measurable, biopsy-accessible
cancers *
• Nina Bhardwaj, M.D., Ph.D., Icahn
School of Medicine at Mount
Sinai, New York, NY
• Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System, Charlottesville, VA
A phase I open label,
multicenter, multi-ascending
dose trial evaluating the safety,
tolerability, and immunogenicity
of intramuscular recombinant
NY-ESO-1 protein with GLASE adjuvant in patients with
unresectable or metastatic cancer
expressing NY-ESO-1
• Immune Design, Seattle, WA
A phase II study to evaluate the
clinical efficacy and safety of
standards of care in combination
with checkpoint blockade in
patients with glioblastoma*
• David A. Reardon, M.D.,
Dana-Farber Cancer Institute,
Boston, MA
Phase I/II study of chemoimmunotherapy with Toll-like
receptor 8 agonist motolimod
and checkpoint blockade in
subjects with recurrent, platinumresistant ovarian cancer for whom
pegylated liposomal doxorubicin is
indicated
• George Coukos, M.D., Ph.D.,
University Hospital of Lausanne,
Lausanne, Switzerland
A multi-peptide vaccine plus Tolllike receptor agonists in melanoma
patients, with evaluation of the
injection site microenvironment for
resected stage IIB-IV
• Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System, Charlottesville, VA
A phase I study of cancer vaccine
CHP-NY-ESO-1 in combination
with Poly-ICLC in patients with
esophageal cancer or malignant
melanoma expressing NY-ESO-1
• Hiroshi Shiku, M.D., and Shinichi
Kageyama, M.D., Mie University
School of Medicine, Mie, Japan
A phase I study of concomitant
WT1 analog peptide and NY-ESO-1
• David O’Malley, M.D., The Ohio
State University Wexner Medical
Center, Columbus, OH
• Paul Sabbatini, M.D., Memorial
Sloan Kettering Cancer Center,
New York, NY
A phase I study of vaccination
with NY-ESO-1 protein mixed with
Poly-ICLC, OK-432 (Picibanil®), and
ISA-51 (Montanide®) in patients
with advanced cancers expressing
NY-ESO-1
• Yuichiro Doki, Ph.D., and Hisashi
Wada, M.D., Ph.D., Osaka
University, Osaka, Japan
A phase IA/IB study of vaccination
with NY-ESO-1 protein, Poly-ICLC,
and mogamulizumab in patients
with adult T cell leukemia/
lymphoma expressing NY-ESO-1
• Yuzuru Kanakura, Ph.D., and
Hiroyoshi Nishikawa, M.D., Ph.D.,
Osaka University, Osaka, Japan
A phase II open label randomized
study of Poly-ICLC-matured
dendritic cells as an adjuvant for
NY-ESO-1 and MELANA/MART-1
peptide vaccination compared to
Montanide ISA-51 in patients with
melanoma
• Nina Bhardwaj, M.D., Ph.D., Icahn
School of Medicine at Mount
Sinai, New York, NY
A pilot study of a novel
multimodality immunochemotherapy platform for
patients with advanced cutaneous
T cell lymphoma
• Catherine M. Diefenbach, M.D.,
NYU Langone Medical Center,
New York, NY
A pilot study of the
immunogenicity of a 9-peptide
breast cancer vaccine plus PolyICLC in stage IB-IIIA breast cancer
• Patrick M. Dillon, M.D., University
of Virginia Health System,
Charlottesville, VA
A preclinical mouse vaccination
experiment to compare the
effectiveness of Poly-ICLC to that
of the more common QS-21
• Samuel Danishefsky, Ph.D.,
Memorial Sloan Kettering Cancer
Center, New York, NY
A trial to evaluate the
immunogenicity and safety of a
melanoma helper peptide vaccine
plus novel adjuvant combinations
• Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System, Charlottesville, VA
LEENA GANDHI, M.D.,PH.D.
Evaluation of safety and
immunogenicity of a multiphosphapeptide vaccine plus
Poly-ICLC in participants with
melanoma
• Victor H. Engelhard, Ph.D.,
and Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System, Charlottesville, VA
General research purposes
(Poly-ICLC)
• Fathia Mami-Chouaib, Ph.D.,
Institut Gustave Roussy,
Villejuif, France
General research purposes
(Poly-ICLC)
• OncoPep, Inc.,
North Andover, MA
Phase I study of NY-ESO-1 protein
+ Poly-ICLC +/- Montanide®
ISA-51 VG vaccine in patients with
advanced malignant melanoma
• Nina Bhardwaj, M.D., Ph.D., Icahn
School of Medicine at Mount
Sinai, New York, NY
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
27
Phase I/II trial of a long peptide
vaccine (LPV8) + Toll-like receptor
agonists for resected stage IIB-IV
• Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System, Charlottesville, VA
Role of Toll-like receptor 3
in macrophage-mediated
programmed cell removal
of tumor cells
• Irving Weissman, M.D., Stanford
University School of Medicine,
Stanford, CA
Safety and immunogenicity of
vaccination with XAGE1b long
peptides combined with PolyICLC in patients with stage III/IV
pulmonary adenocarcinoma
• Christian Taube, M.D., and
Maarten L. Zandvliet, Ph.D.,
Leiden University Medical
Center, Leiden, The Netherlands
CARL H. JUNE, M.D.
CORRELATIVE AND
LABORATORY STUDIES
Maha Ayyoub, Ph.D., Institut
Gustave Roussy, Villejuif, France
Early-phase NY-ESO-1 clinical
trials in patients with epithelial
ovarian, fallopian tube, or
primary peritoneal carcinoma
and monitoring of tumor-specific
immune responses
Nina Bhardwaj, M.D., Ph.D., Icahn
School of Medicine at Mount Sinai,
New York, NY, and Anna C. Pavlick,
D.O., NYU Langone Medical
Center, New York, NY
Phase II study of CTLA-4 blockade
and low dose cyclophosphamide
in patients with advanced
malignant melanoma after failure
of at least one prior therapy
Sacha Gnjatic, Ph.D., Icahn School
of Medicine at Mount Sinai,
New York, NY
Immunological monitoring for
Cancer Vaccine Collaborative trials
Elke Jäger, M.D., Krankenhaus
Nordwest, Frankfurt, Germany
Core support for NY-ESO-1
clinical trials
Daniel E. Speiser, M.D., University
Hospital of Lausanne, Lausanne,
Switzerland
Vaccination of melanoma patients
(stage II-IV) with ImmuFact IMP321,
tumor antigenic peptides, and
Montanide
Danila Valmori, Ph.D., Centre de
Lutte Contre Le Cancer NantesAtlantique, Nantes-Saint Herblain,
France
Early-phase NY-ESO-1 clinical
trials in patients with epithelial
ovarian, fallopian tube, or
primary peritoneal carcinoma
and monitoring of tumor-specific
immune responses
REAGENT MANUFACTURE
Production of NY-ESO-1
overlapping peptides for use in a
variety of trials
PolyPeptide Laboratories San
Diego, San Diego, CA
Poly-ICLC stability testing
Oncovir, Inc., Washington, DC
LEVERAGED GRANTS
Special partnerships to explore
novel preclinical and clinical studies
in high-priority research areas.
James P. Allison, Ph.D., The
University of Texas MD Anderson
Cancer Center, Houston, TX, and
Antoni Ribas, M.D., Ph.D., UCLA
Medical Center, Los Angeles, CA
Cancer Immunology Translational
Research Dream Team:
Immunologic checkpoint blockade
and adoptive T cell transfer in
cancer therapy
In partnership with the
Entertainment Industry Foundation/
Stand Up To Cancer
Carl H. June, M.D., and Gregory L.
Beatty, M.D., Ph.D.
Perelman School of Medicine at
the University of Pennsylvania,
Philadelphia, PA
Mesothelin-specific chimeric
antigen receptor (CAR) T cell
therapy for pancreatic cancer
In partnership with the
Lustgarten Foundation
DESIGNATED GRANTS
Grants to support research
projects and public education
and awareness initiatives for
which, in most cases, donors have
specifically raised funds.
American Association for
Cancer Research*
Collaboration on Cancer
Immunology Research
Timothy N.J. Bullock, Ph.D.
University of Virginia Health
System, Charlottesville, VA
Enhancing immune therapy for
brain metastases with focused
ultrasound
In partnership with the Focused
Ultrasound Foundation
George Klein, M.D., D.Sc.*
Karolinska Institutet,
Stockholm, Sweden
Studies on Epstein-Barr virus
oncogenes and tumor suppressor
genes, tumor immunology, and
inhibition of tumor cell growth by
stroma cells
In partnership with the
Concern Foundation
ANNUAL AWARDS
In addition to providing financial
support to researchers and
investigators, CRI also honors
scientists and community leaders
with achievement awards.
WILLIAM B. COLEY AWARD FOR
DISTINGUISHED RESEARCH
IN BASIC AND TUMOR
IMMUNOLOGY
Annual prize given to one or more
scientists whose discoveries in
the fields of immunology or tumor
immunology contribute to the
advancement of immune systembased therapies for cancer.
Glenn Dranoff, M.D.*
Novartis Institute for BioMedical
Research, Cambridge, MA
Alexander Y. Rudensky, Ph.D.*
Memorial Sloan Kettering Cancer
Center, Ludwig Cancer Research,
New York, NY
FREDERICK W. ALT AWARD
FOR NEW DISCOVERIES IN
IMMUNOLOGY
Prize honoring a former
postdoctoral fellow in recognition
of outstanding success in
academia or industry for research
that may have a potentially major
impact on immunology.
AACR-CRI LLOYD J. OLD AWARD
IN CANCER IMMUNOLOGY
Award recognizes an active
scientist whose outstanding and
innovative research in cancer
immunology has had a far-reaching
impact on the cancer field.
Ronald Levy, M.D.*
Stanford University, Stanford, CA
In partnership with the American
Association for Cancer Research
OLIVER R. GRACE AWARD FOR
DISTINGUISHED SERVICE IN
ADVANCING CANCER RESEARCH
Annual prize that recognizes
the contributions of dedicated
laypersons or organizations whose
leadership has had a significant
impact on cancer research.
Kenneth C. Frazier*
Chairman and CEO, Merck & Co.
Lauren S. Veronis*
Trustee, Cancer Research Institute,
and Former President, Irvington
Institute for Immunological
Research
Nina Bhardwaj, M.D., Ph.D.*
Icahn School of Medicine at Mount
Sinai, New York, NY
Malcolm A.S. Moore, D.Phil.*
Memorial Sloan Kettering Cancer
Center, New York, NY
The study of hematopoietic stem
cells and progenitor populations in
normal and cancer cells
Gar Reichman Laboratory
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
29
FUNDRAISING
Powering Progress
to Save Lives
E
verything the Cancer Research Institute does to keep the
momentum of scientific progress moving forward would
not be possible without generous support from individuals,
foundations, and corporations who are as passionate as we are to
see an end to cancer as we know it. The outpouring of generosity
has given us another record-breaking year of fundraising. Together,
contributions to CRI from donors totaled $42.1 million last year—a
signal of donor trust in CRI that will allow us to fund more research
that translates into more lives saved.
From the thousands of individuals who make personal donations,
to the passionate Team CRI members who plan fundraising events
or participate in major endurance events around the country, to
the families who donate yearly in memory of a loved one, and our
trustees who give generously of both their time and money, no gift
to CRI goes unappreciated. These contributions continue to make a
difference in the life of the organization and the impact of its work.
$42.1
MILLION FROM
CONTRIBUTIONS
AND SPECIAL
EVENTS
260+
TEAM CRI
FUNDRAISING
EVENTS
When I ask my friends,
family, and coworkers to
support my fundraising
efforts for CRI, I do so
knowing that any gift,
in any amount, is going
to be used wisely, and
ultimately will help us
stop this terrible disease.
Priyanka Sewhani
Chair, CRI Young
Philanthropists Council
Top Individual Fundraiser, 2016
Answer to Cancer Cycling Event
CRI CEO AND DIRECTOR OF SCIENTIFIC AFFAIRS JILL O’DONNELL-TORMEY WITH FORMER REVLON
CEO LORENZO DELPANI AND REVLON AMBASSADORS OLIVIA WILDE AND HALLE BERRY; NBC
TODAY SHOW HOST MATT LAUER AT THE THROUGH THE KITCHEN PARTY;
SEVEN-YEAR-OLD SAGE DREW PICTURES OF ANIMALS TO RAISE FUNDS FOR CRI;
TEAM CRI RUNNERS IN 2016 UNITED AIRLINES NEW YORK HALF MARATHON;
ST. LOUIS-BASED T-SHIRT COMPANY, TEE TURTLE, RAISED MORE THAN $54,000
To read stories of CRI donors, visit
cancerresearch.org/supporters
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
31
DONORS
Supporting the Cause
T
he Cancer Research Institute’s ability to advance important
science and facilitate the development of immunotherapies for all
types of cancer is made possible through the generous support of
our donors. Acknowledgments listed here reflect contributions of $1,000
and more made to CRI between July 1, 2015, and June 30, 2016.
$1,000,000+
Bristol-Myers Squibb
Anna-Maria and Stephen Kellen
Foundation
MedImmune, Inc.
The Thompson Family
Foundation
$500,000 - $999,999
The Hearst Foundations, Inc.
Merck
Multiple Myeloma Research
Foundation, Inc.
$100,000 - $499,999
Merle S. Cahn Foundation
Clinton Global Initiative
Estate of Prudence Cometa
Concern Foundation
Rose Marie Craig Trust
Mr. and Mrs. Maurice J. Cunniffe
Fight Colorectal Cancer
Genentech
GlaxoSmithKline
Oliver R. Grace
Charitable Foundation
Estate of Inez G. Koch
The Ambrose Monell Foundation
Revlon
Mr. and Mrs. Brian Riano
Estate of Gertrude Schelling
Betsy and Paul Shiverick /
Shelter Hill Foundation
The Estate of John Strang
The Wildflower Foundation, Inc.
$50,000-$99,999
Amgen
AstraZeneca Pharmaceuticals LP
Estate of Stuart Sidney Bernard
Mr. and Mrs. Edgar R. Berner
Bloomberg Philanthropies
Estate of Frederick J. Brand
Jennifer L. Brorsen
and Richard M. DeMartini
Ann and Geoffrey O. Coley
Estate of Salvatore Corsaro
Debevoise & Plimpton LLP
Estate of Ruth Engelberg
Mr. and Mrs. Sean P. Fahey
Georgia and Don Gogel
Janet Greenfield
and Peter L. Bloom
Marlene Hess and James Zirin
Marion Esser Kaufmann
Foundation
F.M. Kirby Foundation, Inc.
Mr. and Mrs. Kenneth G. Langone
Mr. and Mrs. Alexander P. Lynch
The Honorable Colleen
McMahon and Frank V. Sica
Joan Meltesen Unitrust
Andy and Tom Mendell
Orinoco Foundation
Mr. and Mrs. Andrew M. Paul
Linda C. Pinkus Fund of
the Community Foundation
of New Jersey
Regeneron Pharmaceuticals, Inc.
Johanna and Lief D. Rosenblatt
Jeanne and Herb Siegel
Jane and James Stern
Sharzad and Michael Targoff
Tee Turtle LLC
Mr. and Mrs. Andrew K. Tsai
Diane and Tom Tuft
Ueberroth Family Foundation
Lauren and John Veronis
Jim Weiss, W2O Group
Peter Zhou
$25,000-$49,999
Agenus, Inc.
Baird
The Jeanne E. and Jacob A.
Barkey Memorial Fund
WHITE OUT THE PLAZA EVENT
Beazley Group
Kenneth N. Borofsky
Estate of Raymond V. Byrne
Richard E. Capri Foundation
Celldex Therapeutics, Inc.
Clayton, Dubilier & Rice LLC
Frederic R. Coudert Foundation
Leslie and Bob Dahl
Oliver S. and Jennie R. Donaldson
Charitable Trust
The John and Jenny Eckerson
Family Foundation
Albert Nathan Eisenberg
Charitable Foundation
Eli Lilly & Company
The John and Christine
Fitzgibbons Foundation
Sophie Garafola
Goldman Sachs Group, Inc.
Herman B. Golub Charitable Trust
Green Charitable Foundation, Inc.
Mary Gurster
Hagedorn Fund
Jeffrey Hammerbacher
Leonard Lauder
Mr. and Mrs. Ronald S. Lauder
Miltenyi Biotec, Inc.
Estate of Jean Marie Newcomer
Anna Oschwald Trust
Perri Peltz and Eric Ruttenberg
David M. Polen Retirement Plan
Proceeds Trust
Bruce C. Ratner
Mr. and Mrs. Michael A. Roe
Edmond J. Safra Foundation
Edith M. Schweckendieck Trusts
Elena and Scott Shleifer
Wachtell, Lipton, Rosen & Katz
The Wasily Family
Foundation, Inc.
$10,000-$24,999
James P. Allison, Ph.D.
Dr. Eva Andersson-Dubin
and Mr. Glenn Dubin
Anonymous
Ronit and Marc Arginteanu Fund
Yacov Arnopolin
Alixandra Englund Audiberti
Rose M. Badgeley Residuary
Charitable Trust
Judy and Ron Baron
Charles N. Bartunek
Bonbright Family
Foundation Trust
Mr. and Mrs. Charles Bronfman
Jeffrey A. Burki
Mr. and Mrs. Russell L. Carson
James M. Citrin
Corning Incorporated
Karen and Matthew Crews
Mr. and Mrs. Glenn J. DeSimone
Domain Associates, LLC
Dr. and Mrs. Ronald I. Dozoretz
Thea Duell and Peter Cook
Thomas English
Fribourg Family Foundation
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
33
I am so grateful for all the folks that are fundraising and
actively raising awareness with the Cancer Research
Institute, who are helping patients like me who, after failing
all other clinical trials, are looking for the next option.
Ariella
Hodgkin lymphoma survivor treated with immunotherapy
Estate of James Gagliano
Mr. and Mrs. Victor Ganzi
Ambassador Charles A. Gargano
Gratis Foundation
Joyce Green Family Foundation
Heidi Greene and Michael Kluger
Seth Grossman
GuideVine Technologies
The Marc Haas Foundation
Mr. and Mrs. Talbot Hamilton
Shirley & Burt Harris
Family Foundation
Hempleman Family
Charitable Giving Fund
The Hurlbert Family Foundation
The Karev Foundation
Joel J. Kassimir
Megan V. Kearney
and Paul Enright
LabAnswer and Its Employees
The Max, Malie, Dr. Leonard,
and Bernice Laub Family
Foundation
Mr. and Mrs. Matt Lauer
The Ralph and Ricky Lauren
Family Foundation
Dalia and Larry Leeds
Estate of Mildred Leiffer
Florence & Edgar Leslie
Charitable Trust
Estate of Francis R. Linden
Gordon J. Linden
Loncar Investments LLC
The Longhill Charitable
Foundation Inc
Loon Point Foundation
Larry L. Luing Family Foundation
Albert Marino
Nancy L. Mauro
Mr. and Mrs. Wesley McDonald
Estate of Sharon H. McGowan
Emil and Toby Meshberg Family
Foundation Inc.
Morgan Stanley & Co.
Mr. and Mrs. Richard P. Morgenstern
Mr. and Mrs. Jacques C. Nordeman
North State Cancer League
Royce E. Oliver Jr.
Pace, Inc.
PDT, Inc.
Mr. and Mrs. Jeffrey M. Peek
Harlan Peltz
The Research Foundation of CUNY
Carlos Rodriguez-Pastor
The Edward John and Patricia
Rosenwald Foundation
Hillary and Wilbur Ross
Schaumburg Professional
Firefighters BE
Adolph & Ruth Schnurmacher
Foundation, Inc.
The Estate of Louise S. Schoenke
Lori Squire
Mr. and Mrs. Leonard N. Stern
Walter and Louise Sutcliffe
Foundation
Michael Steven Swell
Liz Whitney Tippett Foundation, Inc.
Estate of Zelda M. Uthe
Mr. and Mrs. Ronald G. Weiner,
Perelson Weiner LLP
Wells Fargo
Robert D. Welsh
Lally Graham Weymouth and
Joseph M. Cohen
Whiting Foundation
The Wiggins Foundation, Inc.
$5,000-$9,999
AbbVie Inc.
Gino Adamo’s St. Joseph
Dinner Dance
Alexander and Johannes
Charitable Fund
Jane B. Allen
California Fund of the
Hugh J. Andersen Foundation
Christopher Ankoviak
Anonymous (6)
Backman Research Foundation
C.R. Bard Foundation
Basin Holdings
Mercedes T. Bass
Charitable Corporation
Curtis Bergan
Cathie Black and Tom Harvey
Mr. and Mrs. James C. Blair
Franci J. Blassberg and
Joseph L. Rice III
Borderland 2 on Twitch
The Henry W. Bull Foundation
Pat and Gil Caffray
Kevin Cook
Mr. and Mrs. Richard Corey
Mr. and Mrs. Skip Cressman
Danem Foundation
EisnerAmper LLP
Frank M. Ewing Foundation, Inc.
Mr. and Mrs. Carlos A. Ferrer
Tom Franco
Sam Friedman
Steven M. Galbraith
Mr. and Mrs. Nathan Gantcher
Terrell Gates
Cheryl & Edward S. Gordon
Foundation
J. Ira and Nicki Harris
Family Foundation
Rochelle and David A. Hirsch
Foundation, Inc.
Mr. and Mrs. William D. Hobbs
Innovate International Intelligence
& Integration, LLC
Inovio Pharmaceuticals
Mr. and Mrs. George Kaufman
Richard and Suzanne Kayne
Charitable Fund
Rachel Rutherford Englund Knapp
Mr. and Mrs. David H. Koch
Dr. Donald Kuspit
Charles and Margaret Levin
Family Foundation
Michael Litt
Audra M. Liu
W. Bruce Lunsford
D. Scott Mackesy
Mr. and Mrs. Christopher L.
Marhofer
Evan McDonald-Stewart
Guillaume Mear
Joseph Mitola
Mitsubishi UFJ Securities (USA), Inc.
Dr. and Mrs. Malcolm Moore
Nandanson Charitable Foundation
Newgen Strategies
and Solutions, LLC
NewLink Genetics Corporation
Northfield Bank
Morris W. Offit
Parkell, Inc.
Chris Parry
Vickie and Rahn Pitzer
Pluralsight
Verne C. Powell
Querrey Simpson
Charitable Foundation
The Raether 1985 Charitable Trust
Geoffrey S. Raker
Kristin and Michael Reed
Family Foundation, Inc.
Reed-Lane, Inc.
Mr. and Mrs. Karl Roessner
Daryl and Steven Roth Foundation
Jami Rubin
Peter Craig Russell
Seaman Family Foundation
Kevin W. Sharer
Michael Charles Sharp
Mr. and Mrs. Paul H. Sherry
Mr. and Mrs. Brian Sir
Mr. and Mrs. Craig Smith
Geraldine and Ernest Smith
Socket Telecom LLC
Michael Sorensen
Stainman Family Foundation
Dr. David Staunton
Mr. and Mrs. Allan Stern
Mr. and Mrs. Douglas Stone
Sharon and Tom Teles
The Thom Family Foundation, Inc.
Elizabeth and Jim Tinsman
Venables, Bell & Partners LLC
Paul H. Volpe Revocable Trust
Jeff Webb
Harriet and Ronald Weintraub
Mr. and Mrs. James C. Zelter
$1,000-$4,999
24-7 Auto Transport, Inc.
Qasim Abbas
Richard Abbey
Debbie H. Abbott
Kedar Abhyankar
Abbey and Richard Aborn
Johnson Abraham
Accenture
Mr. and Mrs. Lawrence N. Ackley
John E. Adams
ADI Meetings & Events
Mr. and Mrs. Anthony Aellen
AeroDyn Wind Tunnel LLC
Frank Alberico
John Alexander
Patrick Allare
Louise Allchin
AllianceData
Allied World Assurance Company
Jennifer Almeida
Audrie and Todd Alsdorf
Dr. Amy Alspach
American Hospice Foundation
American Life Group
Richard Ammerman
Tom Ampeliotis
Mr. and Mrs. Dale P. Anderson
Robert G. Andrews
Anonymous (35)
Imane Anys
Fadi Arbid
Ariel Capital Management, LLC
Garo H. Armen, Ph.D.
Henry Arnhold
Jan Aronson
ASA Research
Mr. and Mrs. Joseph Azara Jr.
Michael Babiarz
Katherine and Mark Babin
Darius Babusis
Kevin Baca
Frederico Bandini
Mr. and Mrs. Joseph Bank
Charles B. Banks
Brett Barganz
David Baron
The Barrington Foundation, Inc.
Pamela S. Barry, Ph.D., and
Thomas W. Schneider, Ph.D.
Mary and Thomas Bartlett
Stephen J. Bastone
Mr. and Mrs. Neil Bayer
Robbie and Ted Beaty
Beckman-Matsui
Family Foundation
Mr. and Mrs. Everett A. Bell
THE DONNY G MEMORIAL GOLF TOURNAMENT
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
35
Bell Forest Products
Kathleen Belsten
Joanne Benedict
Mr. and Mrs. Jonathon Berezinski
The Berkowitz Family Foundation
Edward Bermas
Adler Bernard
Mr. and Mrs. Mark Berry
Scott M. Besaw
Bethel Park School District
Mr. and Mrs. Larry D. Billen
Gino V. Birbiglia
The Birchwood Country Club
Incorporated
Mr. and Mrs. James W. Bishop Jr.
Sharon and David Bishop
Carol Biuso
Burke Black
Mr. and Mrs. James A. Block
Kelly and Steve Bloom
Theodore Blumenthal
Stuart H. Bohart
Barnabas Boon
Ted J. Boulanger Trust
Sylvia Bower
Lisa and David Boyle
BP Foundation, Inc.
Brandt & Hochman
Literary Agents, Inc.
Marie Brenner and
Ernest Pomerantz
Samuel Bretheim
Patrick Brett
Bridges Family Charitable Fund
Christian W. Brinkman
Louis J. Briskman
Jess Brown
Judith S. and David B. Brown
William E. Brown
Mr. and Mrs. Mike Brzozowski
Carla J. Buck
Kathy D. Buehne
Mr. and Mrs. Gregory A. Buhl
Chris Burell
Mr. and Mrs. Tom Burman
Caesars Enterprise Services LLC
Mr. and Mrs. John Calicchio
The Campbell Family
Eileen Campbell
and Struan Robertson
Mr. and Mrs. Rohn Campbell
Antonio Campo
Jennifer Cardettino
and Andrew Hite
Virginia and Edward Caress
Family Fund
Harold Carr
Mr. and Mrs. Robert A. Carter
Mr. and Mrs. Patrick Cassidy
The Cayuga Foundation
Dr. Jacob M. Chacko
Dr. David R. Chapman
Patrick Chapman
Rory Chapple
Kevin Charlton
Jenchi Chen
Kurtis Cicero
Eleanor Clain-Stefanelli
Mr. and Mrs. Daniel K. Clark
Suzette Clayton
Clean Slate Media
Mr. and Mrs. Rodney Cobb
Steve Cohen
Michael J. Cohn
James Coil
Jean P. Colaco
Michael Cominotto
Anna Condo
Kevin Conway
Bob Cooper
CeCe Cord
Mr. and Mrs. Ronald Couture
Mr. and Mrs. James R. Coyle
CPAs 4 MDs, PA
Craigslist Charitable Fund
William S. Credle
Mr. and Mrs. Christopher J. Creed
D. Kirk Cromer
Crossler Middle School
Zoe Cruz
CSX Transportation
Lori Cuisinier
and Anthony Hoberman
The Randi and Roger
Cunningham Charitable Fund
Mr. and Mrs. John R. Curtis Jr.
Cushman Family Foundation
The Wayne and Nicole Cypen
Philanthropic Fund at the
Miami Foundation
Thomas Daly
Mr. and Mrs. Barrie M. Damson
Mr. and Mrs. Timothy Danaher
Munir Dauhajre
Mr. and Mrs. Jason Davenport
Gregory J. Davies
Ashley N. Davis
Mr. and Mrs. Gary Davis
Mr. and Mrs. Roberto de Guardiola
Nathalie and Charles de
Gunzberg
Christina De Mi Randa
Dedicated Defined Benefit
Services, LLC
Della Calce Private Foundation, Inc.
Emily and Rutger deQuay
Mr. and Mrs. Paul Dertien
Devonwood Foundation
Sam C. Dicker
Mr. and Mrs. Andrew Dickman
Mr. and Mrs. Michael D. Dillon
Katherine Dines
Mr. and Mrs. John H. Dobbins
Mr. and Mrs. Dennis R. Dodson
Mr. and Mrs. Scott A. Dondershine
Michael Donohue
Scott Dressler
Marie Dudick
Deborah Dumaine
Nancy P. Durr
Melinda Edelcup
Christopher S. Edwards
Mr. and Mrs. Stephen C. Elkin
David Emanuel
Ralph Enderby Survivors Trust
Hiroaki Eto
E. Joseph Evans Charitable Trust
Dr. and Mrs. Anthony B. Evnin
Mr. and Mrs. Benjamin Falchuk
Mr. and Mrs. Thomas E. Falgout
Madeleine Farragher
Stephen P. Farrar
Dean Fearing
Andrew Fernandez
Louise Egdorf Fescine
Finneran Family Foundation
Mr. and Mrs. Winston O. Fitzhugh
John A. Flood
Daniel Flores
Thomas Foley
Joshua Ford
Fort Myers Broadcasting Co.
Fortress Investment Group LLC
ForYourParty.com
Russell Frandin
Ethan Frey - Brookshire Realty
Barry Friedberg
Scott Friedman
Jonathan Gainsley
Carolyn D. Gaites
Neil Gallagher
Danielle and David Ganek
Deborah Garcia
John A. Gardner
Linda M. Gase
The Estate of Fritz Gautschi
GE Foundation
Genomic Health, Inc.
Mohsen Ghaneian
Marlene Gillis
Kenneth Giuriceo
Mr. and Mrs. David Glendinning
Mr. and Mrs. Kenneth H. Globus
Joseph Godley
Victoria L. Goldberg
Max Goldenberg Foundation
Andrew Goldman
Ellen M. Golub
Charitable Foundation
The Goodman-Lipman Family
Foundation Inc.
Dan L. Goodwin
Gotham Color
Ken Gottesman
Mr. and Mrs. Jason Gottlieb
Walter J. Grandfield
Jillian Griffiths
Aline and Richard Grimes
Kathryn Grossman
Guardians of Cridhe
Mr. and Mrs. William M. Gutowitz
HackerAgency
Edward E. Haddock, Jr.
Family Foundation
Joshua D. Hall
Troy Halterman
Margaret H. Hamachek
The Hampton Landing Co., LLC
Adam D. Handwerker
Mr. and Mrs. Lee M. Hanger
Charlevoix County Community
Foundation - Hanna
Family Fund
Mr. and Mrs. Robert Hanscom
Estate of Victor E. Hansen
Fleur and Leonard Harlan
The Harris Family Charitable Fund
Bethany Harris
Eleanor and Steven Harris
Mr. and Mrs. William B. Harrison
Dr. and Mrs. William A. Haseltine
Melinda Hassen
Thomas Hassen
Tyler Hassen
Mr. and Mrs. Michael Haus
Kathryn L. Haw
THROUGH THE KITCHEN PARTY AT THE FOUR SEASONS RESTAURANT;
ANSWER TO CANCER CYCLISTS; LABANSWER AND ITS EMPLOYEES
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
37
It was an honor to play a
small role in the process
that will sustain cancer
immunotherapy into the
future.
Julian Suchman
Team CRI runner,
TCS New York City Marathon
Mr. and Mrs. Robin Hayes
Ms. Gale Hayman and
Dr. Richard S. Bockman
Head Family Trust
Donald B. Hebb Jr.
Margaret J. Heiser
Alexandra B. Helms
Tad R. Herz
Beth Hickey
Ed Hicks
Higgins Charitable Trust
James Higgins
Reid T. Hironaga
Dr. and Mrs. Frank Hoefflin
Paul C. Hoehne
Burt M. Hoffman Attorney At Law, LLC
Christopher Hogan
Hogan Lovells US LLP
Jessica Holfman Lujan
Kathleen and David Hollows
HorrorHound
Mr. and Mrs. Richard C. Hosley II
Eric Howard
John Howard
Hudson Americas L.P.
Kathleen Hughes
Maritza Hurtado
HzW Environmental Consultants
Ideal Image of Delaware
Capt. Scott Ingraham
Integrus, LLC
Mr. and Mrs. Marc J. Isaacs
Mr. and Mrs. Seymour Israel
E. Marion Jacknow
Deborah and Arthur Jacobson
The James Jacobson Family Fund
Kate and Jeff Jaenicke
George and Janet Jaffin Foundation
Jakal Booster Club
Janklow Foundation
Elizabeth M. Jennings
Tina Jicha
Donald Joh
Johri Family Charitable Foundation
Anne and Johnny Jones
Austin Jones
JP Morgan Chase Foundation
Rebecca and Michael Juneau
Dr. Basim Kadhim
Mr. and Mrs. Neil R. Kardos
Mr. and Mrs. Howard Kaye
Mr. and Mrs. Jerrel W. Kee
Mr. and Mrs. Terry Keller
Mr. and Mrs. William Keller
Edna Kelley
Veronica and Ray Kelly
Mr. and Mrs. Richard Kerns
Keurig Green Mountain
Mr. and Mrs. Bradley D. Kevern
Alena Kim
Ken Kinslow
William Kissling
Mr. and Mrs. Brandon Kistler
Mark E. Klein
Jerry Kleinman
Robert Klett
Shannon Kline
Koko Fitclub of Minnesota
Miss Laine Koman
Mr. and Mrs. Richard F. Kossik
Takashi Kousaka
Andrew Kratz
John Krenicki
Ivan Kriakov
Brenda Kulick
Mr. and Mrs. Kevin Kuntz
Perry A. Kupietz
Mr. and Mrs. David P. Kusel
Mark Kwan
Sheila Labrecque
Mr. and Mrs. Benjamin Lambert
Harlos R. Larrowe
Laser Image
Carey F. Lathrop
The Jeremy Lau Fund
Dr. Lena and Professor Peretz Lavie
Martha and Drahomir Lazar
The League of Legends Community
Laura Ledford
Elizabeth Lee
Michelle Leeds
Mr. and Mrs. Ben Lefkowitz
Morris and Lillie Leibowitz
Charitable Trust
Mr. and Mrs. Craig Lemle
David Lender
Dr. and Mrs. Philip R. Lesorgen
Mr. and Mrs. Francis L’Esperance
Dr. Andrei Levin
Richard and Emily Levin Foundation
John S. Levy
Mary Lynne Levy
William Li
Life Time Marketing, LLC
Anthony Lin
Tullia Lindsten, M.D., Ph.D., and
Craig B. Thompson, M.D.
Mr. and Mrs. Jerry Lis
Daniel C. Litchfield
Chris Lloyd
Brad Loncar
Heather Long
Longboard Asset Management LLC
Timothy and Leslie Lucas
Charitable Fund
William C. Lucia
Brian Luing
Donald L. Lundholm
Peter Lyon
Lynn E. Lyons
Mr. and Mrs. Bruce R. MacDonald
Macheist LLC
Dr. Thomas Mack
Robert S. Madden
Madhatter’s Tea Party
Thomas Maheras
Chris & Melody Malachowsky
Family Foundation
Laurie and Jay Mandelbaum
William Mansfield
Mr. and Mrs. Michael Maranto
Mariel Foundation
Beverly and John Marino
Jane Martin and Stuart Katz
Mr. and Mrs. Redge A. Martin
Mr. and Mrs. Steve Martin
Richard A. Martini
Martins Construction Corporation
Michael M. Marzban
Jeffrey A. Mason
Mr. and Mrs. Allen R. Mass
Dr. Philip Mastman
Ellen C. Mathias
John D. Mauro
Jeffrey S. May
Roy ‘Rem’ Mayes
Dorothy McCabe and Lee Kuntz
David McElligott
Christopher McGarrigal
Kate A. McKay
Christine McKenney
Robert M. McKeon
Kelly McKernan
Vincent McLaughlin
Mr. and Mrs. Michael A. McMurphy
Derek McTyier
Medtronic
Mehul Fund
Richard Meier Foundation
Susan F. Melson
The Sue and Eugene Mercy, Jr.
Foundation, Inc.
Joan Meyers
Michael Edwards Direct, Inc.
Mr. and Mrs. Galem W. Millard
Mr. and Mrs. Craig Miller
Diane L. and Donald L. Miller
Barry Minkoff
Jahid Mirza
Mr. and Mrs. John Mitchell
Hiromasa Mizushima
MJD Concepts, Inc.
Esmail Mobarak
Afshin Momtaz
Gordon and Betty Moore
Foundation
Mr. and Mrs. Paul D. Moran
Pauline K. Morgan
Emily Morningstar
Dr. Robert Moskowitz
Erik Mouthaan
Dr. Jason Much
Mr. and Mrs. Bill Mullins
Pamela Anne Murphy
Vanitha Murugesan
Maria Isabel Nadal De Puigdorfila
Jenks Necker Charitable Fund
Deborah Newsome-Smith
Kevin K. Nickel
Barbara Nielsen
Jon Nite
Norwalk High School
Notre Dame Academy
John Nowak
Jeffrey Nuechterlein
Brandon Nutter
Rebecca and Douglas Obletz
Melissa and Charles O’Brien
Mr. and Mrs. Gregory A. Odle
Christine Ogata
Carolyn J. O’Hara
Mr. and Mrs. James A. Olson
Mr. and Mrs. John Orlando
Daniel O’Shaughnessy
Twila I. O’Sullivan
Elma and Fred Otto
Joe Oziel
Packer Family Charitable Fund
Michael Palmer
Yvonne S. Palmer
Dr. Vernon L. Pankonin
Lee A. Paree
Darryl L. Parrish
Kelly and Gerry Pasciucco
Lasantha Pathirana
Joseph A. Patrick Foundation, Inc.
Camilo Patrignani
Patterson Companies Inc.
China Pavilion
Alan Petersen
Jeffrey A. Peterson
Dr. and Mrs. Frank Petitio
Pew Charitable Trusts
John C. Peyrebrune
Ashley R. Piggush
Mr. and Mrs. Patrick Pijanowski
James Pinto
Mr. and Mrs. Michael J. Pizzo
Gerald Policastro
William Pollock
Ana Luisa Ponti
Mr. and Mrs. Robert A. Posner
Andrew W. Potash
PPD Development, LP
Austin J. Preslar
Paul Pressler
Mr. and Mrs. Michael J. Price
T. Rowe Price Foundation, Inc.
Puglisi Family 2014 Charitable
Giving Fund
Qualcomm
Roberto Quarta
Igor Rabin
Races for Awareness
Renate and Walter Rados
James A. Randel
Tammy and Eric Rasmussen
Terrie L. Ray
Reactive Systems
Recover Painting, LLC
Red Hat, Inc.
Douglas Rediker
Richard B. Reed
Hulda and Michael Refermat
Dawn E. Refsell
Matthew Reischl
Mr. and Mrs. Jerrid Rezin
Chad E. Richman
Kurt Riemenschneider
Mr. and Mrs. Jonas J. Rieter
Dr. Erika Riley
Mr. and Mrs. David Riparbelli
Mr. and Mrs. Herald L. Ritch
Robert P. Rittereiser
Anna Rockler
Rebecca Rogers
Dr. and Mrs. Leon Root
Steven M. Rosenberg Fund
Mrs. Abraham Rosenthal
Jane Rosenthal and Craig Hatkoff
Barry D. Roy
Francois R. Roy
Richard P. Royer
Laurette Rup
Robert Rushton
MAKEUP ARTIST JESSICA HAZE
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
39
ANNUAL AWARDS DINNER AT THE METROPOLITAN CLUB; #WHITEOUTCANCER EVENT AT
MEDIMMUNE/ASTRAZENECA; AND ANSWER TO CANCER CYCLING TEAM BRISTOL-MYERS SQUIBB
The Rust Family Foundation
Sallay Family Fund
Stanley Saltzman
Francine M. Sandoval
Mr. and Mrs. Adarsh Sarma
Rose Ann Scamardella
Scanning America, Inc.
Heather Schimmel
Schluter Systems L.P.
William O. Schmale
Lauren A. Schmidt
Rick Schnall
Karen A. and Henry P. Schneider
Mike Schoeben
June and Paul C. Schorr III
Dr. David N. Schrier
Schulman Family Foundation
Henry C. Schulte and Virginia M.
Schulte Foundation
Larry R. Schuneman
James M. Scrivanich
Brian Searcy
Hooman Sedighi
Mr. and Mrs. Thomas L. Seifert
Karen Shapiro
Stephen Shapiro
Jane Sharp
Dan Shedrick
Cynthia Sheets
Shell Oil Company Foundation
Rocky John Sherer
Raechelle B. Sherman
Jonathan Shipman
The Susan S. Shiva Foundation
Showin’ for a Cure
Mr. and Mrs. Brian D. Silverman
Anne Silverstein
Edward R. Simmons
Simplistics, Inc.
The Simpson Foundation
Linda G. Singer
Nate Sleeper
Laura J. Sloate
Lois V. Smigel
Mr. and Mrs. Gordon H. Smith
Mr. and Mrs. Jeffrey Q. Smith
Mary F. Smith Family Foundation
Nora M. Smith
Patrick Smith
Mr. and Mrs. Scott Sokol
Mr. and Mrs. Howard Solomon
Solutions By Design II, LLC
Anne Spencer
William Spero
Michael Spitzenberger
Kristen Sproat Colley
St. Luke’s Lutheran Church
Paul Stagg
Edgar Stanley
Bonnie M. and Robert J. Stapleton
The Honorable and
Mrs. Kenneth W. Starr
Michael Starr
Mary K. Steffens Foundation
Beatrice Stern
Patricia Stohler
Bonnie and Tom Strauss
Stuntz Family Foundation
Mayo S. Stuntz
Sweet/Polak Charitable Fund
Marc Tabah
Mr. and Mrs. Kok Chor Tan
Jesyca Tang
Joshua L. Targoff
Nicki Taylor and the Cuddlebugs
Jean and Kenneth Telljohann
Tennis League Network, LLC
Texarkana Jeep Junkies Club
Mr. and Mrs. Jeffery Thomas
Marc Thomson
Thomson Reuters
Mr. and Mrs. Andrew H. Tisch
Dr. and Rev. David C. Tontonoz
William Topham
Mr. and Mrs. Alex Toppin
Alain Tranchemontagne
Mr. and Mrs. John Trousdale
Paul Trunk
TTX Company
Mary Ann Tuft
Timothy F. Turitto
Allen M. Turner
Dr. Lynn H. Turner
USPA Liz Freel Classic
Nancy and Jim Utaski
Utility Contracting Co.
Mr. and Mrs. Jeffrey K. Valentine Sr.
Anne and Philip Vander Haar
Csaba Vandor
J.J. Venturini
Village of Long Creek
Maintenance Corporation
The Villages Theater Company
Millie Viqueira and Steven Miller
VMware Foundation
John Vogel
Mr. and Mrs. Lance Volland
The Kathleen B. and Charles R.
Walgreen III Foundation
Robert B. Walker
Richard N. Walsh
Barbara Walters
Carrie L. Walworth
Jeff Ware
Joseph Warren
Carolyn and David Wasserman
Watermark Learning
Sandra J. Wattier
Web Decisions Group
Steven E. Weigand
The Weingarten Schnitzer
Foundation
Helen and Tom Welling
Wendell Family Foundation
S. Kyle Wesson
Elizabeth G. Weymouth
Gerald I. White
The Wild Unknown
David T. Wiley
Joanna Williams
Greg Wilson
Patricia M. Wilson
Mr. and Mrs. Dennis Winans
Greg Wirth
Michael J. Wisdom
The Wise Family Trust
Carole and Michael Witte
Michael Woinsky
Elaine and Jim Wolfensohn
Gregg S. Wolpert
Mr. and Mrs. William Worthington
WowToyz
Melissa Yannis-Grand
Stephen Yegelwel
Strauss Zelnick
Zenith Ventures, Inc.
J.L. Zrebiec
Mr. and Mrs. Jeffrey Zucker
Joan R. Zuckerman
Marc Zuckerman
Barry Zurbuchen
Helen Coley Nauts Society
The Helen Coley Nauts recognizes
donors who have included the
Cancer Research Institute in their
estate plans. Through deffered
gifts, bequests, trusts, and other
planned giving instruments, these
thoughtful individuals safeguard
the Institute’s financial future. The
Society is named in honor of Helen
Coley Nauts, CRI’s founder. If you
would like to learn more about
making a planned gift, please
contact Rupinder Kaur at
[email protected] or
(212) 688-7515.
Estelle Abas
Peter Adams
Abigail Alderman
Olga Aleskas
Mildred E. Alexander
Frederick E. Allard
Edith M. Amateau
Peggy Anderson
Anonymous (6)
Frances Antopol
Freda S. Armstrong
Grace Arnold
Geneva A. Arthur
Millie L. Arvanites
Ruth Ascher
Virginia and Rex Ashdown
Lee Asher
Belle Asherman
Alice Auerbach
Norman W. Austin
Jeanne Avegno
Else Baier
Maureen and Charles Baker
Olga Baker
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
41
Marion Balen
Ella R. Banks
Mary R. Baque
Dorothy Barbeau
Jeanne E. and Jacob A. Barkey
Mr. and Mrs. Kenneth Barmore
Connie Barnes
William Barr
Florence and Ben Barrack
Rose Barrow
Isabella Williams Bartholow and
Bruce Burdette Bartholow
Etta Baum
Evelyn Beekman
Frank L. Bell
Germaine Benesch
William A. Berkey
Stuart S. Bernard
Lucille Bernot
Herta J. Bernstein
Vincent L. Bessey
Linda Bielat
Grace M. Bishop
John Bittel
Guy Bjorkman
Leslie J. Blain
Anna H. Blankstein
Paula J. Blatter
Ruth Evelyn Bodbyl
Eleanor Bodnar
Ronald J. Bogus
Nancy E. and Lawrence H. Bonander
Mary Borbeck
Rita Borenstein
Robina C. Bouchard
Ted J. Boulanger Trust
Anna Isabel Boyd
Hugh R. Boyd
Barbara Brown Boyer
Frederick Brand
Joy B. Breidling
Lucille Brents
A. Arthur Bressman
Brian M. Brewer
Victor E. Broll
Albert N. Brooks
Minnie E. Brown
Virginia Bruner
Alfred R. Brunner
Anne Luise Buerger
Lucille A. Buland
Mary C. Bundy
Arthur Burkhardt
Lois M. Burns and Robert W. Burns
Dale T. Butterwick
Joy Biggs Buttle
Raymond V. Byrne
Ann W. Calaski
Marilyn and David Callahan
Tracy Campbell
Angelina Carbone
Alfred Carlucci
Julia Carlucci
Pandora Rudland Carroll
Donald O. Carswell
Melba Case
Mary Elizabeth Catto
Doris M. Clanin
William James Clapp
Rodney Cobb
William H. Coffee
Bernice Cohn
Gwendolyn Colburn
Mr. and Mrs. Raymond Cole
Edythe E. Coleman
Bradley L. Coley Jr.
Louis Comedy
Prudence Cometa
Phyllis L. Conley
Vivian E. Conner and Ross I. Conner
Lottie M. and Charles H. Cook
Salvatore Corsaro
Audrey Cowan
Rose Marie Craig
Eleanor H. Cromley
Elmira Crosby
Julia B. and John R. Curtis
Vincent D’Amico
Annabelle L. Danzig
Carleen V. Davis
Alice Dawes
Aileen Adele De Long
Eustis Dearborn
Richard M. DeMartini
Emma Deters
Carolyn S. Detweiler
Betty Disbrow
Adelaide J. Dodge
Sandford Dody
Michael Dorner
Mary Ann Draus
Blanche Elizabeth Eckerts
Rita Eggert
Dorothy M. Eiser
Earl R. Elliott
Pauline E. Elliott
Ralph Enderby
Ruth Engelberg
Valera L. Ennis
Helen Epstein
Nathan Epstein
Max G. Eriksen
Helen B. Esokait
Florence L. and Ned A. Etkin
Juanita M. Evans
Mary S. Fadeley
Helen Jean Falk
Herbert Lynn Fann
Barbara Feldman
Robert I. Fendrich
Carlos A. Ferrer
Adelaide E. Ferris
Louise Egdorf Fescine
Elsie K. Filonchik
Mary H. and Frances E. Flood
Josephine Fonti
Florence A. Forni
Bernard W. Forrest
Carole D. Franklin
Clay Frazier
Lucille O. French
Alice M. Fried
Anne Fruhner
Lena Silverstein Fuhrman
James Gagliano
Gay H. Gahagan
Zoltan Galdi
Eugene G. Gallant
Peter Gallant
Mollie E. Gang
Sophie Garafola
Salvador Garcia
Carole Gardner
B.I. Garlinghouse
Fritz Gautschi
Thomas J. Gearing
E. Yvonne and William O. Geisert
Stella Gentile
Mildred Gentry
Penelope M. Georgiadis
Mercedes C. Gerhard
Patricia J. Getsfried
Janet M. Gifford
Regina Gilmour
Steven D. Ginsberg
Edna E. Glaessel
Eleanor Goldberg
Philip Goldblatt
Raymond J. Gordinier
Doris Gordon
Jean R. and John G. Gosnell
Norman Gottlieb
Dorothy M. Graham
E. Ruth Grant
Annette and Owen Gray
Bernice E. Grilleaux
Floyd Dale Grisham
Zoe S. Grove
Noreen Bryce Gruebl
Ronald J. Guglielmino
Anna Guhring
Marianne C. Hafner
Jeanine Hair
Nelle B. Haire
Adrian Leroy Hall
Diane Ham
Mr. and Mrs. Virgil Hamby
Frances E. Hanneman
The Hansen Trust
Lydia C. Hanson
Loretta D. Hardy
Mark L. Hariton
Evelyn H. Harris
Lori Harris
Ottis C. Harris
Helaine T. Harrison
Yetta Hatch
Anne M. Hauser
James Leon Hawkins
Margaret Hayman
Clarence E. Hedberg
Donald P. Heim
Virginia Hemme
Robert J. Hendry
Fredrick Charles Henne
Senora Henry
Marion Hewett
Kay Hilton
Margot Hoffmann
Nurine Hoke
Eva M. Holmes
Diane and Don Holmes
Nellie Huff
Grace M. Humphrey
Mary L. Hutchins
Idell E. and Fred W. Iltner
Madeline Inguagiato
Ruby R. Jankiewicz
Lynn and Eldon Jasper
Warren R. Jecklin
Doreen and Basil Joffe
Ruth Harvey Johnson
Doris Kabat
Rosemary Kaplan
Sally J. Kaplan
David Katz
ANSWER TO CANCER CYCLING TEAM W2O; #WHITEOUTCANCER SUPPORTERS AT NBC TODAY SHOW PLAZA
Sara Katz
Bertha E. Kaufman
Samuel Kay
Blanche C. Kelly
Jean Kemp
Hugh W. Kennedy
Mercedes E. Kent
Elsie E. Kiel
Corinne Kiell
Theresa A. Kiely
Mary B. Kilroe and Edward L. Kilroe
Barbara Kincaide
Hilda Kirson
Shirlene Kisak
Marilyn and Robert Klett
Ruth and Hugo Klotz
Anne Koch
Inez G. Koch
Truby Joy Kohl
Mr. and Mrs. Harry Kompanek
Juanita and Fred Koors
Harry A. Kraus
Mary T. Kraus
Naomi P. Kruse
Murray Kupferman
Hiroko Kyuba
Rose Lachow
Sidney G. LaDue
Anna Lagstein
C. Linda Lambert
Jewell Marie Lampkin
Marguerite Landis
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
43
Louise G. Lane
Caryl Lou Langford
Elizabeth S. Larkin
AnneMarie LaValle
Mildred Leiffer
Florence and Edgar Leslie
Polly Annenberg Levee
James F. Levens
Frances Leventritt
Betty Lou Levin
Esther Levine
Beatrice Levy
Simon Lifshatz
Francis R. Linden
Harvey A. Linden
Patricia A. Lindner
George H. Lindskog
Roseline Lissak
Frances M. Lizak
Johanna Loeb
Ruby Q. Lokensgard
Peter J. Lommen
Bonnie Long
Albie A. Adams Loving
Madeline Lukowitz
Mr. and Mrs. William H. Lyford
Gertrude A. Lynch
Hjordes Diane Lyttle
Eleanor D. MacCracken
Emilie Machalinski
Catriona Macleod
William S. Maddenborough
David Madsen
Henrietta Malbin
Herbert J. Maletz
Isabelle C. Malone
Anna Malowany
John Malowany Trust
Ferne Magialardo
Meyer Marcus
B.M. Marinko
Genevieve Martin
Louemma Martin
Lowell A. Martin
Raleigh L. Martin
Blanca Mattalia-Wyrzykowski
Mildred G. Matz
Donald Maurer
Lourdes Mayuyu
Margaret Mazzey
Michael I. McBride
Helen McCann
Cecil McClernon
Annette McDonald
Sharon H. McGowan
J. Donald McKinney Jr.
Norma J. McPherson
Jan Mears
Grace Muriel Mecchi
Joan Meltesen
Nancy Jeanne Merkel
Sidney Meskin
Ethel L. Meyer
Ezilda Michel
Helen T. Middleton
Dorothy Mae Miller
William D. Miller
Alex Mitchell
Maha Mohamed
Mr. and Mrs. Charles G. Moore
Janet P. Morgan
Maza D. Morris
Louise and Peter Moseychuk
Bryant A. Muenzen
Alexander Munchweiler
Irene R. and Martin F. Murphy
Judith K. Murphy
Kathryn T. Murphy
Thomas P. Murray
Naomi Myers
Mayumi Nakagawa and John K. Lai
Rita Nasser
Alice A. Nauts
Patricia Navarro
Paula M. Neal
Barbara Lynne Nelson
Rose E. Nelson
Jean Marie Newcomer
Freda E. Newton
and William E. Newton
Herb H. Nichols
Bernard R. Niewoehner
Geneva W. Nolen
Jacques C. Nordeman
Mary M. Nowak
Mary Nunez
Dorothy B. Nurick
Margaret M. and Harry A. Oak
Nora Odets
Arvilla Ogden
Michele A. Ognibene
Roselyn R. Olken
Alice Orlich
Mary O’Rourke
Anna and Paul Oschwald
Albert Ottinger
Lily Pace and Floyd Pace
Marjorie W. Packwood
Erma N. Panfilio
Andrew Reid Paton
Eleanor T. Patterson
Carmen F. Patti
Foster Clae Patton
Frederick V. Payne
Nancy Elizabeth Pease
April Peck
Donald H. Peper
Agnes Phelps
Elizabeth F. Phillips
John Piercy
Harriet-Anne Pierson
Rochelle Pinz
Cynthia Joy Platt
Dorothy Plumb
Mabel Plunkett
Nick J. Pokea
David M. Polen
Esther Posin
Richard Potruch
Despina Poulos
Clifford Presky
Joyce A. Prime
Dorothy S. Pritchard
Aspasia Radoumis
Carol Diane Ranken
James B. Ransohoff
Esther Reed
Harry Delos Reich
Helen Relkin
Floris J. Renk
LaDonna Reynolds
James F. Rice
Florence V. Richardson
Adam J. Richter
Virginia L. Riddle
Robert T. Ridley
Michael Riley
Adeline Ringeisen
Dr. Fred Ringel
Veronica A. Rose
Susan Rosenberg
Ilene Roth
Leah Roth
Moises Rubiano
Dorothy and Ernest Rueppel
Gloria Ruminsky
Hedwig Salzer
Margaret E. Sammons
Lydia B. Scannell
Gertrude Schelling
Martha Schneller
Louise S. Schoenke
Virginia Schuettpelz
Helen R. Schutt
Ruth Schwartzman
Rev. Harold Bend Sedgwick
Dorothy K. Sefcovic
Francine Segall
Clara Senk
Natalie Shebs
Dorothy M. Sheese
Margaret Sheets
Donald Sherwood
Renee and Irwin Shishko
Laura M. Sidener
Lottie Siegel
Katherine U. Silva
Belle V. Silverstein
Augusta Simon
Roma Sinclair
Estelle Singer
Jean V. Sirles
Alice Jean Smith
Catherine M. Smith
Clarence Smith
Mr. and Mrs. Ernest B. Smith
Howard G. Smith
Kevin L. Smith
Patricia Smith
Willie Mae Smith
Ruth Sneve
Vera Marie Snider
Esther and Harold Sohmer
Fred E. Spencer
Jacqueline Spencer
William Sprenger
Remy R. Sprouse
Brenda M. St. James
Gerald J. Steinberg
Leopold Steindecker
Anna Stephan
Robert L. Stevens
Mary Malcolm Stiles
John Strang
Fay Strout and Laurence Cecil Strout
Frieda Coons Studley
Dorothy H. Sullivan
Myrtle B. Summers
Agnes Katscher Sunley
John Supon
Mary and James Suthard
Mary Carol Talerico
Maureen Tannehill
Melvin G. Taylor
George C. Thomas Jr.
Carl E. Thomas
Geraldine E. Thomas
Overton Arnold Thompson
Viola Mae Thompson
Anita and John R. Timmel
Carola S. Trier
Jessie C. Tripp
John D. Turkel
Zelda M. Uthe
Paul E. Van Cleve
William R. Vass
Josephine S. Villeman
Myrtle H. and Antone L. Vinelli
Anne D. Vinton
Paul H. Volpe
Linda Vono
Esther and Stanley Wade
Ethel Wagner
David Walker
Robert B. Walker
Thomas Walsh
Julia Walz
Lea Ward
Irene M. Watkins
Dorothy Waugh
Ione A. and Albert L. Weickert
Rose C. Weisel
Elizabeth A. Weiser
Leonard Weiss
Robert P. West
Anna M. Wheeler
Lois V. Wheeler
Agnella L. Widmer
Geneva K. Widmer
Margaret Wiegandt
Saul J. Wiener
Loretta M. Wiggins
Lorna Katherine Wilkinson
Francis I. and Harriet B. Wilks
Josephine H. Williams
Ora Brown Windle
Mr. and Mrs. Norman J. Woodhams
Frederick W. Woodworth
Carolyn and Bill Woody
John A. Wootton
Josephine Wootton
Nettie Wright
Ethel R. Young
Marion E. Youngberg
Gloria Zaino
Marion Zell
Raelynn and Steve Ziegler
Centennial Circle
The Centennial Circle celebrates
donors who have made a lifelong
commitment to supporting
the Cancer Research Institute.
Members of this loyal group have
made 75 or more gifts to CRI
during their lifetime.
Anonymous (2)
Ellen Beloff
Mr. and Mrs. Ira M. Boskey
Brian M. Brewer
Lauren B. Burns
Harriet E. Charles
Mr. and Mrs. Irving Cohen
Aileen Cole
Selma Davidson
Archibald M. Denny III
Mr. and Mrs. Stephen C. Elkin
Rhoda Fischman
Anne E. Gentile
Mr. and Mrs. Gary R. Ginsberg
Mr. and Mrs. Leonard Gold
Oliver R. Grace Jr.
Helen A. Green
Renee A. Harris
Harvey A. Herbert
Mrs. Stephen M. Kellen
Col. Richard C. Kowalski
Mr. and Mrs. Elliot Leitner
Mr. and Mrs. Michael Levy
Charles J. Lurie
Mr. and Mrs. Charles Lyttle II
Thomas G. Mendell
Mr. and Mrs. Arthur Nasso
Jacques C. Nordeman
Bernadette Nuzzo
Maxwell D. Osborne
Esther Ravin
Mr. and Mrs. Jonas J. Rieter
Mr. and Mrs. Milton S. Rubin
Clifford M. Rutter
Joyce Schumer
Mr. and Mrs. Sydney Shuman
Mr. and Mrs. Brian D. Silverman
Mr. and Mrs. Marvin Stillman
William Tracy
Timothy D. Tucker
Mr. and Mrs. Everett L. Wessner
Alan N. White
Florence Wisler
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
45
FINANCIAL
HIGHLIGHTS
Your Gift at Work
D
onor trust is something we value above all else. To earn and
maintain this trust, we hold ourselves to the highest standards
of accountability and transparency when communicating the
financial health of this organization. Seeking to extract maximum
impact from every dollar donated, we fund strategically and invest
responsibly, keeping an eye to the long view of progress while
remaining nimble enough to respond to new opportunities. Our
financial records are kept according to best accounting practices,
and we open our books annually for inspection and verification by
independent auditors.
EisnerAmper has conducted an independent audit of the Cancer
Research Institute’s financial activities for fiscal year 2016 (July 1,
2015, to June 30, 2016). We provide highlights here, and you can
access our complete audited financial statements on our website at
cancerresearch.org/financials.
PUBLIC SUPPORT & REVENUE (Unrestricted)
$
33.7MM
Contributions
$26.9MM, 80%
includes $9.9MM raised in
prior years for FY2016 operations
Special Events
$2.7MM, 8%
Investments & Other
$2.2MM, 6%
87
PERCENT OF
EXPENSES
DEDICATED TO
PROGRAMS
$336
MILLION
INVESTED
SINCE 1953
Bequests & Memorials
$2.0MM, 6%
The continued financial
strength of this
organization stems not
only from the generosity
of our donors, but also
from the rigorously high
standards of accountability
to which we hold ourselves.
OPERATING EXPENSES
$
31.5MM
Research
$22.6MM, 72%
$23.6MM awarded minus $909K in early
terminations from grants made in prior years
Education
Alfred R. Massidas
Chief Financial Officer
$4.8MM, 15%
Marketing & Fundraising
$2.8MM, 9%
Administration
$1.2MM, 4%
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
47
GOVERNANCE
& GUIDANCE
Providing
Expert Oversight
V
olunteer scientific and business leaders help the Cancer
Research Institute, not only through academic and financial
support, but also through astute governance and active
participation in the organization’s initiatives.
BOARD OF TRUSTEES
CHAIRMEN
Paul C. Shiverick
Co-Founder
Seminole Management
Company, Inc.
New York, NY
Andrew K. Tsai
Managing Principal
Chalkstream Capital Group, L.P.
New York, NY
VICE CHAIRMEN
Edgar R. Berner
Partner
John Lang, Inc.
New York, NY
John B. Fitzgibbons
Chairman and CEO
Basin Holdings US LLC
New York, NY
TREASURER
Geoffrey O. Coley
International Business Head
Mitsubishi UFJ Securities (USA), Inc.
New York, NY
SECRETARY
Thomas G. Mendell
Private Investor
T.G. Mendell Corp.
New York, NY
BOARD
Yacov Arnopolin
Portfolio Manager,
Emerging Markets
PIMCO
New York, NY
Peter L. Bloom
Brooklyn, NY
Jennifer L. Brorsen
Bronxville, NY
Donald J. Gogel
Chairman and CEO
Clayton, Dubilier & Rice, LLC
New York, NY
James M. Citrin
Leader, CEO Practice
Spencer Stuart
Stamford, CT
Jacques C. Nordeman
Chairman
Nordeman Grimm, Inc.
New York, NY
Maurice J. Cunniffe
Chairman and CEO
Vista Capital Corporation
Greenwich, CT
Andrew M. Paul
Managing General Partner
Enhanced Equity Funds
New York, NY
W. Robert Dahl
Principal
WRD Capital
Darien, CT
Glenn J. DeSimone
Greenwich, CT
John E. Eckerson
Rye, NY
Sean P. Fahey
Founding Member and
Co-Chief Investment Officer
Claren Road Asset Management
New York, NY
Margot E. Freedman
Larchmont, NY
Oliver R. Grace Jr.
President
Associated Asset Management, Inc.
Palm Beach, FL
Sandra Coudert Graham
Oyster Bay, NY
Michael M. Kellen
Director of First Eagle Holdings, Inc.
Vice Chairman of First Eagle
Investment Management, LLC
New York, NY
Alexander P. Lynch
Partner
White Deer Energy
New York, NY
Brian Riano
Co-Founder and CEO
Claren Road Asset Management
New York, NY
Lief D. Rosenblatt
Partner
ENE Investco Management
New York, NY
Frank V. Sica
President
Tailwind Capital
New York, NY
James A. Stern
Chairman and Founder
The Cypress Group, LLC
New York, NY
Michael B. Targoff
Vice Chairman of
the Board of Directors
Loral Space & Communications
New York, NY
Diane Tuft
New York, NY
Heidi J. Ueberroth
Director
Pebble Beach Company
Pebble Beach, CA
Lauren S. Veronis
New York, NY
Ronald G. Weiner
President
Perelson Weiner LLP
New York, NY
CRI trustees are fully engaged
in our mission because each
of us believes in the potential
of immunotherapy to conquer
all cancers, and each has seen
how CRI is able to transform
this potential into reality for
many cancer patients today.
John B. Fitzgibbons
Chairman and CEO,
Basin Holdings US LLC
Vice Chairman,
CRI Board of Trustees
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
49
Jim Weiss
Founder and CEO
W2O Group
San Francisco, CA
Peter Zhou
Senior Managing Director
Coatue Management
New York, NY
Mrs. Charles G. Gambrell
Charlotte, NC
ASSOCIATE BOARD
CHAIRMAN
William O. Grabe
Advisory Director
General Atlantic LLC
Greenwich, CT
Joyce Green
Westhampton Beach, NY
Tyler Hassen
President
Basin Power
New York, NY
Howard P. Berkowitz
HPB Associates
New York, NY
Donald G. Calder
Chairman
Clear Harbor Asset Management
New York, NY
Stuart P. Davidson
Managing Director
Labrador Ventures
San Francisco, CA
Bruce D. Dixon
Retired Partner
Ernst & Young
Greenwich, CT
Ann W. Jackson
New York, NY
Arthur L. Jacobson
Vice President, Investments
Smith Barney
Indian Wells, CA
Robert A. Posner
Managing Director
Commonwealth Holding, LP
Brookline, MA
Julian H. Robertson Jr.
Chairman
Tiger Management, LLC
New York, NY
Winthrop H. Smith Jr.
Chairman
Summit Ventures NE, LLC
Warren, VT
SCIENTIFIC ADVISORY
COUNCIL
Niko Gubernator, Ph.D.
Chief Executive Officer
eMolecules
La Jolla, CA
James P. Allison, Ph.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX
Nick Hammerschlag
Founder and Managing Partner
Martellus Holdings
New York, NY
ASSOCIATE DIRECTORS
Adler Bernard
Counsel
JPMorgan Chase & Co.
New York, NY
Jennifer Box, CFA
Managing Director
Oaktree Capital Management, L.P.
New York, NY
Rada Cevher
Business Development
Wealth-X
New York, NY
Eash Cumarasamy
Chief Financial Officer
Basin Industries
New York, NY
Edward Donkor
Principal, Energy
Investment Team
Pine Brook Partners
New York, NY
Michael Fisher
Vice President
Enhanced Equity Funds
New York, NY
Samantha Knapik
Consultant
Fortress Investment Group
New York, NY
Trent Kososki
Principal
Energy Capital Partners
Short Hills, NJ
Maggie Moore
Vice President,
Urban Investment Group
Goldman Sachs
New York, NY
Ashton Valente
General Counsel
Basin Holdings
New York, NY
Harvey Cantor, M.D.
Dana-Farber Cancer Institute
Boston, MA
DIRECTOR
MEMBERS
TRUSTEES EMERITI
Carter F. Bales
Chairman and Managing Director
NewWorld Capital Group, LLC
New York, NY
Andrew Goldman
Managing Director
Anchorage Capital Group
New York, NY
Glenn Dranoff, M.D.
Novartis Institutes for
BioMedical Research
Cambridge, MA
Carl F. Nathan, M.D.
Weill Cornell Medicine
New York, NY
Jonathan S. Cebon, Ph.D., FRACP
Austin Health/Ludwig Cancer
Research
Melbourne, Australia
Vincenzo Cerundolo, M.D., Ph.D.
MRC Human Immunology Unit,
University of Oxford
Oxford, United Kingdom
Max D. Cooper, M.D.
Emory University
School of Medicine
Atlanta, GA
Ellen Puré, Ph.D.
University of Pennsylvania
Philadelphia, PA
Lisa M. Coussens, Ph.D.
Knight Cancer Institute
Oregon Health & Science
University
Portland, OR
Robert D. Schreiber, Ph.D.
Washington University
School of Medicine
St. Louis, MO
Peter Cresswell, Ph.D.
Yale University
School of Medicine
New Haven, CT
Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan Kettering
Cancer Center and
Ludwig Cancer Research
New York, NY
Charles G. Drake, M.D., Ph.D.
NewYork-Presbyterian/
Columbia University
Medical Center
New York, NY
MEMBERS
Michael L. Dustin, Ph.D.
University of Oxford
Oxford, United Kingdom
Frederick W. Alt, Ph.D.
Boston Children’s Hospital and
Harvard Medical School
Boston, MA
Richard Axel, M.D.
Columbia University
Medical Center
New York, NY
Nina Bhardwaj, M.D., Ph.D.
Tisch Cancer Institute,
Icahn School of Medicine
at Mount Sinai
New York, NY
Richard A. Flavell, Ph.D., FRS
Yale University
School of Medicine
New Haven, CT
Thomas F. Gajewski, M.D., Ph.D.
The University of Chicago
Chicago, IL
Laurie H. Glimcher, M.D.
Dana-Farber Cancer Institute
Boston, MA
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
51
Philip D. Greenberg, M.D.
University of Washington School
of Medicine and Fred Hutchinson
Cancer Research Center
Seattle, WA
Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA
Patrick Hwu, M.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX
Elizabeth M. Jaffee, M.D.
The Sidney Kimmel
Comprehensive Cancer Center,
Johns Hopkins University
School of Medicine
Baltimore, MD
Carl H. June, M.D.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania
Philadelphia, PA
Michael Kalos, Ph.D.
Eli Lilly & Company
New York, NY
Michael Karin, Ph.D.
University of California, San Diego
La Jolla, CA
John M. Kirkwood, M.D.
University of Pittsburgh
Cancer Institute
Pittsburgh, PA
George Klein, M.D., D.Sc.
Karolinska Institute
Stockholm, Sweden
Alexander Knuth, M.D.
National Center for Cancer Care
and Research, Hamad Medical
Corporation
Doha, Qatar
Lewis L. Lanier, Ph.D.
University of California,
San Francisco
San Francisco, CA
Hyam I. Levitsky, M.D.
Juno Therapeutics
Seattle, WA
Dan R. Littman, M.D., Ph.D.
NYU Langone Medical Center
New York, NY
Nils Lonberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA
Tak W. Mak, Ph.D., D.Sc., FRSC
The Campbell Family Institute
for Breast Cancer Research
at Princess Margaret Hospital,
University Health Network,
University of Toronto
Toronto, Canada
Klaus Rajewsky, M.D.
Max-Delbrück Center
for Molecular Medicine
Berlin, Germany
Mark J. Smyth, Ph.D.
QIMR Berghofer Medical
Research Institute
Queensland, Australia
CVC TRIALS NETWORK
Anjana Rao, Ph.D.
La Jolla Institute for Allergy and
Immunology, Sanford Consortium
for Regenerative Medicine
La Jolla, CA
Pramod K. Srivastava, M.D., Ph.D.
University of Connecticut
Health Center
Farmington, CT
Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan Kettering Cancer
Center and Ludwig Cancer
Research
New York, NY
Jeffrey V. Ravetch, M.D., Ph.D.
The Rockefeller University
New York, NY
Stanley R. Riddell, M.D.
Fred Hutchinson Cancer
Research Center
Seattle, WA
Philippa C. Marrack, Ph.D.
National Jewish Health and the
University of Colorado Denver
Denver, CO
Alexander Y. Rudensky, Ph.D.
Memorial Sloan Kettering
Cancer Center
New York, NY
Cornelis J.M. Melief, M.D., Ph.D.
Leiden University Medical Center
Leiden, The Netherlands
Bijan Safai, M.D., D.Sc.
New York Medical College
Valhalla, NY
Ira Mellman, Ph.D.
Genentech
South San Francisco, CA
Shimon Sakaguchi, M.D., Ph.D.
Immunology Frontier Research
Center, Osaka University
Osaka, Japan
Malcolm A.S. Moore, D.Phil.
Memorial Sloan Kettering
Cancer Center
New York, NY
Lawrence E. Samelson, M.D.
National Cancer Institute, NIH
Bethesda, MD
Lee Nadler, M.D.
Dana-Farber Cancer Institute
Boston, MA
Hans Schreiber, M.D., D.MSc., Ph.D.
The University of Chicago
Chicago, IL
Kunle Odunsi, M.D., Ph.D.
Roswell Park Cancer Institute
Buffalo, NY
Ton N. Schumacher, Ph.D.
The Netherlands Cancer Institute
and Kite Pharma
Amsterdam, The Netherlands
Drew M. Pardoll, M.D., Ph.D.
The Sidney Kimmel
Comprehensive Cancer Center,
Johns Hopkins University
School of Medicine
Baltimore, MD
Craig L. Slingluff Jr., M.D.
University of Virginia
School of Medicine
Charlottesville, VA
Susumu Tonegawa, Ph.D.
Massachusetts Institute of
Technology
Cambridge, MA
Giorgio Trinchieri, M.D.
National Cancer Institute, NIH
Frederick, MD
DIRECTOR AND SCIENTIFIC
ADVISORY COMMITTEE CHAIR
SCIENTIFIC ADVISORY
COMMITTEE
Jonathan S. Cebon, Ph.D., FRACP
Austin Health/Ludwig Cancer
Research
Melbourne, Australia
Ulrich H. von Andrian, M.D., Ph.D.
Harvard Medical School and
Boston Children’s Hospital,
Boston; The Ragon Institute of
Massachusetts General Hospital,
MIT, and Harvard University
Cambridge, MA
George Coukos, M.D., Ph.D.
University Hospital of Lausanne
(CHUV)
Lausanne, Switzerland
Hao Wu, Ph.D.
Boston Children’s Hospital and
Harvard Medical School
Boston, MA
Cassian Yee, M.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX
Rolf M. Zinkernagel, M.D., Ph.D.
University of Zürich
Zürich, Switzerland
Antoni Ribas, M.D., Ph.D.
UCLA Medical Center
Los Angeles, CA
Michel Sadelain, M.D., Ph.D.
Memorial Sloan Kettering
Cancer Center
New York, NY
Neil H. Segal, M.D., Ph.D.
Memorial Sloan Kettering
Cancer Center
New York, NY
Nina Bhardwaj, M.D., Ph.D.
Icahn School of Medicine at
Mount Sinai
New York, NY
Emil R. Unanue, M.D.
Washington University
School of Medicine
St. Louis, MO
Robert H. Vonderheide, M.D., D.Phil.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania
Philadelphia, PA
Kunle Odunsi, M.D., Ph.D.
The Roswell Park Cancer Institute
Buffalo, NY
Lawrence Fong, M.D.
University of California, San
Francisco
San Francisco, CA
Dirk Jäger, M.D.
National Center for Tumor
Diseases, University of Heidelberg
Heidelberg, Germany
Elizabeth M. Jaffee, M.D.
Johns Hopkins University School
of Medicine
Baltimore, MD
Carl H. June, M.D.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania
Philadelphia, PA
Andrew G. Sikora, M.D.
Baylor College of Medicine
Houston, TX
Craig L. Slingluff Jr., M.D.
University of Virginia
Cancer Center
Charlottesville, VA
Pramod K. Srivastava, M.D., Ph.D.
University of Connecticut Health
Farmington, CT
Marcel R.M. van den Brink, M.D., Ph.D.
Memorial Sloan Kettering
Cancer Center
New York, NY
Robert H. Vonderheide, M.D., D.Phil.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania
Philadelphia, PA
E. John Wherry, Ph.D.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania
Philadelphia, PA
Matthew F. Krummel, Ph.D.
University of California,
San Francisco
San Francisco, CA
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
53
FINANCE, INTELLECTUAL
PROPERTY, CLINICAL
TRIALS MANAGEMENT, AND
ADMINISTRATION
CANCER RESEARCH INSTITUTE
Adam Kolom
Vanessa M. Lucey, Ph.D., MBA
Jill O’Donnell-Tormey, Ph.D.
LUDWIG CANCER RESEARCH
Pär Olsson, Ph.D.
Aileen Ryan
Jonathan Skipper, Ph.D.
Ralph Venhaus, M.D.
GLOBAL CLINICIAN AND
SCIENTIST MEMBERSHIP
UNITED STATES
• James P. Allison, Ph.D.,
The University of Texas
MD Anderson Cancer Center
• Shahab Asgharzadeh, M.D.,
University of Southern California
• Djordje Atanackovic, M.D.,
University of Utah
• Mark Awad, M.D., Ph.D., DanaFarber Cancer Institute
• Nina Bhardwaj, M.D., Ph.D., Icahn
School of Medicine at Mount
Sinai
• Margaret Callahan, M.D., Ph.D.,
Memorial Sloan Kettering
Cancer Center
• Timothy A. Chan, M.D., Ph.D.,
Memorial Sloan Kettering
Cancer Center
• Aude G. Chapuis, M.D., Fred
Hutchinson Cancer Research
Center
• Hearn Jay Cho, M.D., Ph.D., Icahn
School of Medicine at Mount
Sinai
• Adam D. Cohen, M.D., University
of Pennsylvania
• Patrick Dillon, M.D., University of
Virginia Health System
• Gavin P. Dunn, M.D., Ph.D.,
Washington University School
of Medicine
• Lawrence Fong, M.D., University
of California, San Francisco
• Leena Gandhi, M.D., Ph.D., NYU
Langone Medical Center
• Sacha Gnjatic, Ph.D., Icahn
School of Medicine at Mount
Sinai
• Philip D. Greenberg, M.D.,
Fred Hutchinson Cancer
Research Center, University of
Washington
• F. Stephen Hodi Jr., M.D., DanaFarber Cancer Institute, Harvard
Medical School
• Siwen Hu-Lieskovan, M.D., Ph.D.,
UCLA Medical Center
• Elizabeth M. Jaffee, M.D., Johns
Hopkins University School of
Medicine
• Carl H. June, M.D., University of
Pennsylvania
• Achim Jungbluth, M.D.,
Memorial Sloan Kettering
Cancer Center
• Thomas J. Kaley, M.D., Memorial
Sloan Kettering Cancer Center
• John M. Kirkwood, M.D.,
University of Pittsburgh Medical
Center
• Matthew F. Krummel, Ph.D.,
University of California, San
Francisco
• Alexander M. Lesokhin, M.D.,
Memorial Sloan Kettering
Cancer Center
• Kunle Odunsi, M.D., Ph.D.,
Roswell Park Cancer Institute
• Hideho Okada, M.D., Ph.D.,
University of California, San
Francisco
• Drew M. Pardoll, M.D., Ph.D.,
Johns Hopkins University
School of Medicine
• Marshall R. Posner, M.D., Icahn
School of Medicine at Mount
Sinai
• Osama E. Rahma, M.D.,
University of Virginia Health
System
• David A. Reardon, M.D., DanaFarber Cancer Institute
• Antoni Ribas, M.D., Ph.D., UCLA
Medical Center
• Michel Sadelain, M.D., Ph.D.,
Memorial Sloan Kettering
Cancer Center
• Yvonne Saenger, M.D., Columbia
University Medical Center
• Jonathan D. Schoenfeld, M.D.,
M.Phil., MPH, Dana-Farber
Cancer Institute
• Neil H. Segal, M.D., Ph.D.,
Memorial Sloan Kettering
Cancer Center
• Padmanee Sharma, M.D., Ph.D.,
The University of Texas
MD Anderson Cancer Center
• Andrew G. Sikora, M.D., Ph.D.,
Baylor College of Medicine
• Craig L. Slingluff Jr., M.D.,
University of Virginia Health
System
• Alexandra Snyder Charen,
M.D., Memorial Sloan Kettering
Cancer Center
• Pramod K. Srivastava, M.D.,
Ph.D., University of Connecticut
School of Medicine
• Mario Sznol, M.D., Yale Cancer
Center
• Suzanne L. Topalian, M.D., Johns
Hopkins University School of
Medicine
• Cornelia L. Trimble, M.D., Johns
Hopkins University School of
Medicine
• Takemasa Tsuji, Ph.D., Roswell
Park Cancer Institute
• Marcel R.M. van den Brink, M.D.,
Ph.D., Memorial Sloan Kettering
Cancer Center
• Robert H. Vonderheide,
M.D., D.Phil., University of
Pennsylvania
• Ralph R. Weichselbaum, M.D.,
University of Chicago
• E. John Wherry, Ph.D., University
of Pennsylvania
• Jedd D. Wolchok, M.D., Ph.D.,
Memorial Sloan Kettering
Cancer Center, Ludwig Cancer
Research
• Cassian Yee, M.D., The
University of Texas MD
Anderson Cancer Center
• Dmitriy Zamarin, M.D., Ph.D.,
Memorial Sloan Kettering
Cancer Center
• Hassane M. Zarour, M.D.,
University of Pittsburgh
Medical Center
• Lei Zheng, M.D., Ph.D., Johns
Hopkins University School of
Medicine
EUROPE
• Maha Ayyoub, Ph.D., Institut
Gustav Roussy, Villejuif, France
• Luigi Buonaguro, M.D., National
Cancer Institute Pascale, Italy
• Vincenzo Cerundolo, M.D., Ph.D.,
University of Oxford, United
Kingdom
• George Coukos, M.D., Ph.D.,
University Hospital of Lausanne,
Switzerland
• Jessica Cecile Hassel, M.D.,
University Clinic of Heidelberg,
Germany
• Dirk Jäger, M.D., University Clinic
of Heidelberg, Germany
• Elke Jäger, M.D., Krankenhaus
Nordwest, Germany
• Lana E. Kandalaft, Pharm.D.,
Ph.D., University Hospital of
Lausanne, Switzerland
• Judith Kroep, M.D., Ph.D., Leiden
University Medical Center, The
Netherlands
• Simon A. Laban, M.D., University
of Ulm, Germany
• James Larkin, FRCP, Ph.D., The
Royal Marsden NHS Foundation
Trust, United Kingdom
• Xin Lu, Ph.D., University
of Oxford, Ludwig Cancer
Research, United Kingdom
• Cornelis J.M. Melief, M.D., Ph.D.,
Leiden University Medical
Center, The Netherlands
• Mark R. Middleton, M.D., Ph.D.,
University of Oxford, United
Kingdom
• Dario Neri, Ph.D., Swiss Federal
Institute of Technology Zürich,
Switzerland
• Christian Ottensmeier, M.D.,
Ph.D., FRCP, University of
Southampton, United Kingdom
• Pedro J. Romero, M.D.,
University Hospital of Lausanne,
Switzerland
• Daniel E. Speiser, M.D.,
University Hospital of Lausanne,
Switzerland
• Danila Valmori, Ph.D., Centre de
Lutte Contre Le Cancer NantesAtlantique, France
• Nicolas Van Baren, M.D.,
Ph.D., Université Catholique
de Louvain, Ludwig Cancer
Research, Belgium
• Maries van den Broek, Ph.D.,
University of Zürich, Switzerland
• Benoit J. Van den Eynde, M.D.,
Ph.D., Université Catholique
de Louvain, Ludwig Cancer
Research, Belgium
• Pierre van der Bruggen,
Ph.D., Université Catholique
de Louvain, Ludwig Cancer
Research, Belgium
• Sjoerd Henricus van der Burg,
Ph.D., Leiden University Medical
Center, The Netherlands
• Magnus von Knebel Doeberitz,
M.D., University Clinic of
Heidelberg, Germany
• Alfred Zippelius, M.D., University
of Basel, Switzerland
ASIA
• Shinichi Kageyama, M.D., Mie
University School of Medicine,
Japan
• Alexander Knuth, M.D., National
Center for Cancer Care and
Research, Hamad Medical
Corporation, Qatar
• Eiichi Nakayama, M.D., Ph.D.,
Kawasaki University of Medical
Welfare, Japan
• Hiroyoshi Nishikawa, M.D.,
Ph.D., National Cancer Center
Hospital, Japan
• Hiroshi Shiku, M.D., Mie
University School of Medicine,
Japan
• Hisashi Wada, M.D., Ph.D., Osaka
University, Japan
The Clinical Accelerator
has a network of nearly
90 leading cancer
immunologists across
12 countries, who bring
unparalleled expertise to
the design, planning, and
execution of our clinical
trials.
Adam Kolom
Clinical Accelerator
Australia
• Jonathan S. Cebon, Ph.D.,
FRACP, Austin Health, Ludwig
Cancer Research
• Mark J. Smyth, Ph.D., FAHMS,
QIMR Berghofer Medical
Research Institute
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
55
CANCER IMMUNOTHERAPY
CONSORTIUM
Michael Kalos, Ph.D.
Eli Lilly & Company
New York, NY
STEERING COMMITTEE CHAIRS
Daniel S. Chen, M.D., Ph.D.
Genentech
South San Francisco, CA
Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA
MEMBERS
Cedrik M. Britten, M.D.
GlaxoSmithKline
Stevenage, United Kingdom
Roger D. Dansey, M.D.
Merck Research Laboratories
Rahway, NJ
Glenn Dranoff, M.D.
Novartis Institutes for
BioMedical Research
Cambridge, MA
Robert M. Hershberg, M.D., Ph.D.
Celgene and VentiRx
Pharmaceuticals
Seattle, WA
YOUNG PHILANTHROPISTS
COUNCIL
STAFF
SENIOR STAFF
Shasell Negron
General Manager / Workplace
Giving Campaign Manager
BOARD
Nils Lonberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA
Israel Lowy, M.D., Ph.D.
Regeneron
Tarrytown, NY
Ira Mellman, Ph.D.
Genentech, Inc.
South San Francisco, CA
David M. Reese, M.D.
Amgen
Thousand Oaks, CA
Arvin Yang, M.D., Ph.D.
Bristol-Myers Squibb
Princeton, NJ
Priyanka Sewhani
All About the Optics
New York, NY
Catherine Borod
Partners & Spade
New York, NY
Anna-Nora Bernstein
Freelance Film Producer
New York, NY
Ali Urman
Montefiore Medical Center
New York, NY
Anna Maria Barbuti
St. Johns University
New York, NY
Jill O’Donnell-Tormey, Ph.D.
Chief Executive Officer and
Director of Scientific Affairs
Brian M. Brewer
Director of Marketing and
Communications
Lynne A. Harmer
Director of Grants Administration
and Special Events
Alfred R. Massidas
Chief Financial Officer and
Director of Human Resources
Sharon Slade
Director of Strategic Initiatives
Alexa Schles
Graphic Designer
Devi Sharma
Donations Processing Manager
Marla A. Sincavage
Associate Director, Corporate
and Foundation Relations
Denise Upton
Manager of Grants Administration
Jasmine Wright
Events Coordinator and
Assistant to the CEO
Qing Hua Zhang
Controller
STAFF
CONSULTANT
Samuel Obletz
Goldman Sachs
New York, NY
Marissa Kaplan
Verathon Inc.
New York, NY
Megan Bannigan
Debevoise & Plimpton LLP
New York, NY
Brittany Lett
Cognito
New York, NY
MEMBERS
Natalie Berner
Linda Foit
Sean Kiely
Jaskaren Randhawa
Diana Rosario
Arthur N. Brodsky, Ph.D.
Science Writer
Rupinder Kaur
Senior Manager of Operations
and Officer of Planned Giving
Adam Kolom
Managing Director,
Clinical Accelerator
Michelle Liew
Digital Media Manager
Melinda Lopez
Receptionist/
Administrative Assistant
Vanessa M. Lucey, Ph.D., MBA
Associate Director, Clinical
Venture Fund and Accelerator
Caitlin Mackaman
Manager of Individual Giving
Katherine McCluskey
Event Coordinator
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
57
WAYS TO GIVE
Lasting Impact
T
he Cancer Research Institute has a long tradition of responsible
stewardship of donor funds. We receive the highest marks from
charity watchdog groups, including four out of four stars from
Charity Navigator and an “A” grade from CharityWatch. CRI also meets
all 20 standards of the Better Business Bureau Wise Giving Alliance.
Donors to CRI can be confident that their donation, in any amount, will
do the most good possible.
OUTRIGHT GIFTS
Cash
Donations by check or credit card may be sent directly
to the Cancer Research Institute or processed through
our secure website at cancerresearch.org/donate
Property Other Than Cash
Donating securities, automobiles, and similar properties can
often be a tax-efficient method for making a meaningful gift
to CRI. Visit cancerresearch.org/ways-to-give
Workplace Giving Programs
Ask your human resources department if your company may
have a plan through which you can contribute to CRI, or contact us
to learn how to set up a program at your workplace.
Matching Gifts
You can contact your human resources department to inquire
if your employer matches contributions, or browse our online
matching gift database to see if your company is listed at
cancerresearch.org/match
Planned Gifts
Include bequests made through a living trust or inclusion of the Cancer
Research Institute in your will as a beneficiary of cash, securities, or
personal property. Your bequest should include the Institute’s federal
tax ID number (13-1837442) and a statement such as the following:
“I bequeath to the Cancer Research Institute, a not-for-profit
corporation of the State of New York, having its principal office
at One Exchange Plaza, 55 Broadway, Suite 1802, New York, New
York 10006, the sum of $
for its general operating purposes.”
ALEXANDER M. LESOKHIN, M.D., A CRI-FUNDED CLINICAL INVESTIGATOR AT MEMORIAL SLOAN KETTERING
CANCER CENTER IN NEW YORK, NY, IS TESTING TWO PROMISING CHECKPOINT IMMUNOTHERAPIES,
DURVALUMAB AND TREMELIMUMAB, IN A CLINICAL TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA.
Community Fundraising
Want to hold a bake sale to raise money for cancer research? How
about a fashion show, dinner, or a music concert? Maybe you’re
getting married and would prefer guests give to charity in lieu of
gifts. We offer support for these and other fundraising ideas. Visit
cancerresearch.org/fundraise to learn more about how you can
organize your own special event and become a part of Team CRI.
FOR CORPORATE PARTNERS
No one organization, company, or group can solve the cancer
problem alone. It takes collaboration to change the course of
cancer. CRI actively seeks out and welcomes opportunities to work
together with others to develop educational and awareness-building
programs designed to advance the pace of progress in cancer
immunotherapy research. Contact Sharon Slade at
[email protected] or (212) 688-7515 x230 to learn more.
To help you make the most fitting
and fulfilling contribution to CRI,
please contact our Development
Office at (212) 688-7515
or send an email to
[email protected].
You should, of course, always consult your attorney and tax advisor
for the formal writing of your will and to discuss the tax implications
of any form of planned giving. Learn more online at
legacy.cancerresearch.org.
CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
59
NATIONAL HEADQUARTERS
One Exchange Plaza
55 Broadway, Suite 1802
New York, NY 10006
Tel. (212) 688-7515
Toll-Free (800) 99-CANCER
Fax (212) 832-9376
Email [email protected]
VOLUNTEER OFFICES
344 Hauser Boulevard, Unit 422
Los Angeles, CA 90036
Tel. (323) 935-2520
101 University Avenue, 4th Floor
Palo Alto, CA 94301
Tel. (650) 365-6441
80 Field Point Road
Greenwich, CT 06830
Tel. (203) 622-0522
184 Fisher Avenue
Brookline, MA 02445
Tel. (617) 566-0100
2802 Flintrock Trace, Suite 220
Austin, TX 78738
Tel. (512) 610-5530
122 River Run Road
Lancaster, VA 22503
Tel. (703) 759-0835
CANCERRESEARCH.ORG